

Community- Associated Clostridium difficile Risk Factor Study Protocol

Protocol Version #2

Version Date: 11/25/2013

New Submission

Prepared by Susan Hocevar

Tal	ble of Contents:	Page Number
1.	Protocol Summary	3
2.	Background and Justification	3
3.	Objectives	4
4.	Study Personnel	5
5.	Study Design	7
6.	Protection of Human Research Subjects	17
7.	Progress Evaluation	22
8.	Timeline	22
9.	References	23
10.	Appendices	25

11.

I. Protocol Summary

This study poses no more than minimal risk to the study participants as there will be no interventions or modifications to the care study subjects receive. Emerging Infections Program (EIP) surveillance personnel will identify community-associated *Clostridium difficile* (CA-CDI) cases through existing population-based surveillance for CDI. Cases will be included, based on age, in the adult (≥ 18 years) or child (1-5 years) study groups. Controls will be matched to cases on the basis of age group and gender; a questionnaire will be administered to each participant. Outcomes of this study will include estimates of the magnitude of association between disease status and selected exposures.

II. Background and Justification

The Centers for Disease Control and Prevention (CDC), National Center for Emerging and Zoonotic Infectious Diseases, Division of Healthcare Quality Promotion (DHQP), in collaboration with state public health authorities, plans to assess risk factors for community-associated *Clostridium difficile* infection through the CDC's Emerging Infections Program (EIP).

Clostridium difficile is an anaerobic, spore-forming, gram positive bacillus that produces two pathogenic toxins: A and B. C. difficile infection (CDI) ranges in severity from mild diarrhea to fulminant colitis and death.¹ Transmission of C. difficile occurs primarily in healthcare facilities as environmental contamination by C. difficile spores combined with patient exposure to antimicrobial drugs creates an opportunity for infection. Traditional risk factors for CDI include antibiotic use, advanced age, and prior hospitalization.² CDI increasingly has been reported among young, healthy individuals residing in the

community without traditional CDI risk factors.³⁻⁶ Community-associated CDI is estimated to represent 32% of all CDI based on population-based figures from the Emerging Infections Program,^{5,7,8} with an incidence of 30-40 per 100,000 population in the United States.⁵ Previous reports have shown approximately 40% of patients acquiring community-associated CDI were not exposed to antibiotics,³⁻⁶ suggesting that additional factors may contribute to infections. Although the U.S. Food and Drug Administration issued a communication on February 8, 2012 advising physicians to consider the diagnosis of CDI among patients taking proton pump inhibitors, the data on the association of CDI with proton pump inhibitors are still controversial and studies to quantify this association are needed. In addition to understanding factors that predispose patients to CDI, further evaluation of potential *C. difficile* exposure sources in the community is necessary to guide prevention efforts. Although several sources of *C. difficile* in the community such as food, water, outpatient healthcare environment, and daycare centers have been raised as potential risks, the magnitude of association of these risks with disease development has not been evaluated to date.^{5,6,9,10}.

This case-control study will enable investigators to evaluate these associations and focus future investigations and prevention strategies on those factors identified as significantly associated with disease development.

III. Objectives

This multi-center, population based case-control study of persons with CA-CDI matched with controls will address the following objectives:

- 1. Quantify the magnitude of the association between exposure sources and development of disease for community-associated *Clostridium difficile* infection for the following potential exposure sources :
 - Outpatient healthcare exposures (e.g. dental/doctor's visits)
 - Infants in the home, children in diapers, and children in daycare centers
 - Household member(s) with CDI
- 2. Identify exposures other than antibiotics that can perturb the intestinal microbiome thereby increasing risk for CA-CDI including:
 - Proton pump inhibitors, H2 Blockers, antidepressants
 - Chemotherapy
 - Steroids
 - Food Preferences

IV. Study Personnel

The EIP is a collaborative project of the CDC and ten states. Investigators in the proposed study include personnel from the Division of Healthcare Quality Promotion (DHQP, NCEZID), the Division of Foodborne, Waterborne and Environmental Diseases (DFWED, NCEZID), and EIP-funded university-affiliated and state health department personnel. CDC investigators will be responsible for study design, oversight, analysis and interpretation of data. Investigators from EIP sites (California, Colorado, Connecticut, Georgia, Maryland, Minnesota, New Mexico, New York, Oregon, and Tennessee) will contribute to the study design and will be responsible for enrollment of study subjects, data collection, data entry and analysis, and interpretation of coded data.

EIP CDI site coordinators:

California: Lisa Winston, MD; Joelle Nadle, MD

Colorado: Wendy Bamberg, MD; Helen Johnston, MPH

Connecticut: James Meek, MPH; Carol Lyons, MS, MPH; Danyel Olson MPH

Georgia: Monica Farley MD; Wendy Baughman, MSPH; Andrew Revis, MPH; Olivia Almendares,

MSPH; Zirka Thompson, MPH

Maryland: Lucy Wilson, MD, Sc.M;MPH; Rebecca Perlmutter, MPH;

Minnesota: Stacy Holzbauer, DVM, MPH

New Mexico: Erin Phipps, DVM, MPH;

New York: Ghinwa Dumyati, MD;

Oregon: Zintars Beldavs, MS

Tennessee: John Dunn, DVM, PhD; Brenda Rue, RN, BSN

CDC personnel:

DHQP

CDI Risk-Factor Study Lead: Susan Hocevar, MD

CDI Surveillance Lead: Fernanda Lessa, MD, MPH

CDI Surveillance Coordinator: Jessica Cohen, MPH

Microbiologist: Brandi Limbago, PhD

DFWED:

Senior Epidemiologist: Hannah Gould, PhD, MS

V. Study Design

A. Case Definitions

Case Definition: A case of CA-CDI will be defined as a positive *C. difficile* specimen either by toxin or

molecular assay collected as an outpatient or within 3 days after hospital admission in a surveillance area

resident aged 1 to \leq 5 years or \geq 18 years who did not have a prior positive *C. difficile* assay and a

documented overnight stay in a healthcare facility in the twelve weeks prior to specimen collection.

B. General Inclusion and Exclusion Criteria for Cases and Controls

B.1. Case Enrollment

Eligible Case:

All residents aged 1 year to 5 years and \geq 18 years in the surveillance areas with a positive *C. difficile*

stool by either toxin or molecular assay and without documentation of a prior positive *C. difficile* assay

will be eligible for investigation. This will include children and pregnant women (refer to vulnerable

subjects section on page 17).

Inclusion Criteria for Cases:

1. An eligible CDI case, and

7

- 2. Stool specimen collected as an outpatient or within 3 days after admission, and
- 3. No report of overnight stay in a healthcare-facility during telephone interview

Each person can be enrolled as a case only once during the study period. A person enrolled as a case cannot serve as a control. In order to limit patient's difficulty in recalling exposures, patients will be interviewed as soon as possible after the illness is identified.

Exclusion Criteria for Cases:

- 1. Patient did not have a sample from which a positive *C. difficile* toxin assay or a positive *C. difficile* molecular assay was obtained, or
- 2. Ever reports a *C.difficile* diagnosis prior to the current specimen collection date, or
- 3. Had an overnight stay in a healthcare facility in the 12 weeks prior to specimen collection documented in the medical record or reported during interview, or
- 4. Is not in the age group of 1 year to 5 years and \geq 18 years at the time of stool collection, or
- 5. Is not reachable after 8 unsolicited telephone attempts on at least 6 different dates using a valid telephone number. At least one attempt on a weekend and between 5-8 pm on a weekday should be made, or
- 6. Cannot be interviewed within 90 days after positive *C. difficile* stool collection date, or
- 7. Does not have a telephone number available, or
- 8. Does not speak either English or Spanish, or
- 9. Cannot be matched to an eligible control after 40 attempts, or
- 10. Does not report diarrheal illness (at least 3 watery / loose stools in a 24 hour period) associated with the submission of the clinical specimen from which *C. difficile* was detected, or

- 11. Is deceased or incapacitated (i.e. a proxy will not answer for the case subject), or
- 12. Was not a resident of the EIP catchment area at the time of specimen collection, or
- 13. Does not provide informed consent to participating in the study, or
- 14. Is an inmate in a prison or other correctional facility.

B.2. Control Enrollment

Eligible Control

One control will be identified for each case included in the study. Eligible controls will be matched to cases by age group and gender and will be randomly selected from commercially available lists of residential telephone numbers or from birth registries (i.e. for subjects between 12 and 24 months of age)

A person cannot serve as a control more than once in the study.

Inclusion criteria:

- 1. An eligible control, and
- 2. Resident of the EIP catchment area at the time of matched case's positive *C. difficile* stool collection, and
- 3. Age is within the same age- and gender-strata as the matched case-patient. The age strata are as follows:

CHILDREN	ADULT AGE
AGE GROUP	GROUP
12-23months	18–29 years
24-47months	30-39 years
48-60 months	40-49 years

50-59 years
60-69 years
>70 years

Exclusion criteria:

- 1. Resides outside the EIP catchment area at the time of matched case's *C. difficile* specimen collection, or
- 2. Is not in the age group of 1 year to 5 years and ≥ 18 years at the time of matched case's stool collection, or
- 3. Is not reachable after 8 unsolicited telephone attempts on at least 6 different dates using a valid telephone number. At least one attempt on a weekend and between 5-8 pm on a weekday should be made,
- 4. Reports a history of *C. difficile* diagnosis, or
- 5. History of diarrhea (at least 3 watery / loose stools in a 24 hour period) during the 12 weeks prior to the matched case patients Illness Onset date/ Specimen Date, or
- 6. Reports an overnight stay in a healthcare facility in the 12-weeks prior to the specimen collection date / or onset of illness date of the matched case subject, or
- 7. Cannot be interviewed within 90 days after matched case's positive *C. difficile* stool collection date, or
- 8. Is deceased or incapacitated (i.e. a proxy will not answer for the control subject), or
- 9. Does not speak English or Spanish, or
- 10. Is an inmate in a prison or other correctional facility, or
- 11. Does not provide informed consent to participating in the study.

C. Selection of Controls

We will attempt to enroll one control for each enrolled case. Controls will be matched to cases on gender and age group as described on section V.B.2. Once a case-patient has been interviewed, controls should be enrolled as soon as possible. Controls may be enrolled up to 90 days after the specimen collection date of the matched case, but every effort will be made to enroll them as soon as the matched case interview has been completed.

Controls in all except those aged 1 year to 2 years will be selected from commercially available lists of residential telephone numbers, by EIP catchment, area that include age and gender information on household members, allowing for the rapid identification of households at which an age and gendermatched control might be available for a given case. Birth registries will be used to select controls in the youngest age group (1-2 years of age).

We will use a commercial online database that uses various data sources to determine the age / gender of persons living in households with landline telephone numbers listed in the White Pages. To optimize efficiency in recruiting controls, lists of telephone numbers for a given EIP catchment area and age-gender group will be uploaded by CDC to a secure FTP site for transmission to the sites. The size of each list will vary for each site due to the wide variation in CA CDI case numbers by EIP site and by age group. The transmission will be done at the beginning of the study and as requested during the course of the study. The lists sent to sites will contain phone numbers of possible controls in that age/ gender group as well as mailing address for the head of the household. Phone numbers and address are never entered into study databases. All lists of phone numbers and addresses will be deleted before study completion when no longer needed. To enroll controls, the site will randomly sort the potential age-gender control list once

obtained from CDC. Surveillance staff will call potential controls starting from the top and moving down the list. Every phone call attempt will be logged directly in the spreadsheet. If a control is recruited, the telephone number will be marked as completed and successful. If after 40 attempts to enroll a control for a given case are made unsuccessfully, sites will exclude the case. The second time controls of a specific age/gender group combination need to be recruited staff will start with the next phone number on the sub-list where they had last left off. When the end of a sublist is reached study coordinators will cycle back to the top of the sublist and begin calling phone numbers on the sublist a second time. Up to 8 unsolicited telephone attempts may be made to given telephone number during the course of the study. More than 8 total calls can be made if someone in the household asks to be called back. After completing 8 unsuccessful unsolicited calls, or after learning that a person of the relevant age and gender stratum does not live in the household, or after someone in the household asks to not be called back or hangs up, that telephone number will be marked as completed and unsuccessful, and no additional attempts to contact the household will be made. Calls to enroll controls will be made during weekdays (10am-5pm), weeknights (5:01pm-8pm), and weekends (Saturday 10am-8pm, Sunday noon-8pm).

Because commercial companies are unable to provide reliable age information for very young children, birth registries will be used as the preferred method of selecting controls for case-patients in the 1-2 year (i.e., 12 through 24 months old) age group. Controls may be identified from birth registries within the EIP catchment area. EIP sites will sort these lists by date of birth and will attempt to enroll those with the closest birth dates before and after the matched case-patient's birth date. Efforts will be made to enroll these potential controls, including 8 unsolicited phone calls on at least 6 different dates using a valid telephone number. At least one attempt on a weekend and between 5-8 pm on a weekday should be made.

D. Sample Size Estimates

The sample size estimates in the following tables pertain to identifying risk-factors for CA-CDI. There is limited data on risk factors for CA-CDI and this study will provide the first estimates of odds ratios for certain suspected exposures. A sample size calculation for a 1:1 matched case-control study was done using SAS software, version 9.2 (SAS Institute Inc., Cary, NC). For the adult study group, a conservative sample size calculation was performed using a power of 0.80, an alpha of 0.05, and an estimated prevalence of exposure to infants in diapers in adult control-patients of 10.2%.to detect a matched odds ratio of 2.0 for cases compared to controls. The exposure to infants in diapers was used as risk factor because prior studies have suggested that infants may serve as a source for CDI. The estimated prevalence of exposure to infants in diapers was based on census household data for children less than 4 years of age present in homes (10.2%). Based on these numbers a total sample size of 426 would be required (Table 1). For the pediatric study group, a conservative sample size calculation was performed using a power of 0.80, an alpha of 0.05, and a prevalence of gastric or jejunostomy (G-J) tubes in pediatric cases of 19% to detect a matched odds ratio of 2 for cases compared to controls. G-J tube usage was chosen as the variable of interest in children because previous studies on hospital-associated CDI have demonstrated an association with this method of feeding; the estimated prevalence in cases was noted in these studies. 11 Based on these numbers a total sample size of 468 would be required (Table 1). EIP site CA-CDI case numbers are displayed in Table 2.

Table 1: Sample Size Calculations for Adult and Pediatric Study Groups

Study Group	Odds Ratio	Cases	Controls	Total
Adult	2	213	213	426

Pediatric	2	234	234	468

Table 2: 2011 EIP site Adult and Pediatric CA CDI Cases over twelve months

Month of year	1	2	3	4	5	6	7	8	9	10	11	12	Total
													,
CA-CDI cases	236	235	26	267	25	261	281	268	326	283	279	300	3253
≥ 18 years			2		5								
Pediatric CA-	28	21	19	35	19	16	13	29	24	27	23	25	279
CDI cases 1-5													
years													

E. Enrollment methods

Cases: An EIP staff member or local health department staff in each site will interview case-patients by telephone. Eligible case-patients will be identified through routine EIP active CDI surveillance. Each site will attempt to enroll every eligible patient within the designated age ranges that meet the study inclusion criteria outlined above until the study sample size is met. EIP or local health department staff will contact eligible patients by phone and those who meet inclusion criteria based on the screening form (Refer to Appendix A1 (Adult) and A2 (Child)) will be offered participation in the study. Some sites may choose to perform a preliminary screening of eligible cases using medical records before the patient is contacted for a telephone interview since review of medical records is part of the routine EIP CDI surveillance and approved under CDC protocol #5558. Although protocol #5558 is considered research at CDC, and

it was reviewed and approved by CDC IRB, many of the participating EIP states consider this activity to be non-research, as *C. difficile* is a reportable condition in many EIP sites. Screening will be repeated during the telephone interview. The study subject will be read the verbal consent form (refer to Appendix B) and will be invited to participate in the study if inclusion criteria are met. Verbal consent will be obtained and recorded by the interviewer on the consent form. For children, verbal permission from a parent or guardian will be obtained. The parent or guardian will be the respondent. Case-patients may be enrolled up to 90 days after specimen collection date, but every effort will be made to enroll them as soon as possible after their infection is identified.

Controls: Controls will be recruited from the study population in participating sites as outlined above in the control selection section. EIP or local health department staff will contact eligible controls by phone and those who meet inclusion criteria based on the screening form (Refer to Appendix A1, A2) will be offered participation in the study. Verbal consent (refer to Appendix B) will be obtained and documented on the consent form for every participant that meets inclusion criteria. For children, verbal permission from a parent or guardian will be obtained and the parent will be the respondent.

F. Questionnaires

Two questionnaires were developed; one for adults and one for children. Both questionnaires cover demographic characteristics, clinical history, food preferences, environmental exposures, medications, and healthcare visits (Refer to Appendix C1 (Adult) and C2 (Child)). The difference between children and adult questionnaires are related to underlying conditions and age-specific exposures (e.g. daycare centers). None of the questionnaires include name, address or contact information, or sensitive questions such as sexual activity or use of illegal substances. The exposure period of interest for study subjects will be the

12 weeks before illness onset for all exposures aside from food which will be a diet preference.

Questionnaires will be translated into Spanish. Interviews will be conducted in English or Spanish,
depending on the preference of the person being interviewed. Interviews will take approximately 30
minutes.

G. Data management

Standardized forms will be used to collect information. Completed forms will be kept in a locked file cabinet at the local EIP sites and destroyed at the end of the study. Data will be entered by EIP sites into a password protected database on a secure limited access server. Data will be transferred to CDC through a secure FTP site by the 5th day of every month. No patient identifiers such as name, address, phone number or medical record number will be transferred to CDC. The database will be developed by CDC and deployed to the EIP sites that in turn will be responsible to maintain the database. The addition of EIP site-specific variables will be permitted and these fields, along with case identifiers, will not be submitted to CDC.

H. Data analysis

Data analysis will be performed to identify modifiable risk factors for CA-CDI and quantify the magnitude of the association of these factors. Statistical analysis will be performed at CDC, with input of co-investigators, using SAS software, version 9.2 (SAS Institute Inc., Cary, NC). Matched odds ratios (mOR) and P values will be calculated for univariate and multivariate analysis using conditional logistic regression. Variables from univariate analysis with a P value <0.20 will be included as candidates for the risk model. Multivariate analysis using stepwise conditional logistic regression will be performed to

identify independent risk factors. A two-sided P value of < 0.05 will be considered statistically significant.

VI. Protection of Human Research Subjects

The proposed activity meets the definition for human subjects' research. The prepared protocol will be submitted to CDC under expedited review, and, after CDC review, will be submitted at each EIP site local IRB.

A. Study population

Eligible cases will be identified by existing surveillance for *C. difficile* infection at EIP sites. Eligible cases that meet the study inclusion criteria outlined on section V.B. 1 will be invited to participate in the study. The number of study subjects to be enrolled at each site will vary depending on the size of the population under surveillance and the number of CDI eligible cases identified monthly. All patients between the ages of 1-5 years and 18 years of age or greater with a positive *C. difficile* specimen either by toxin or molecular assay and no previous documentation of a positive *C. difficile* assay will be eligible for the study. Controls will be matched to case-patients by gender and age group and will be identified through either commercially online database that uses various data sources to determine the age / gender of persons living in households with landline telephone numbers listed in the White Pages or birth registries as described on section V.C. of this protocol.

B. Vulnerable subjects

The study will include study subjects from vulnerable populations. Pregnant women are at risk for developing CDI and pregnancy status will be ascertained through interview. Infants less than one year of age will be excluded because distinction between *C. difficile* disease and colonization in this age group has

not been well established and they are not included in the ongoing surveillance system. Children aged 1 year to 5 years will be included. CA-CDI is the most common type of CDI in this age group, and, given that adult risk factors and exposures are likely very different from those of young children, the inclusion of adults only would prohibit the assessment of pediatric risk factors for CA-CDI. Children in the older age groups (>5 years) make up proportionally fewer CA-CDI cases reported to EIP sites indicating that the disease may not be as common in this age group; hence, children ages 1-5 years will be the focus of the pediatric study. This research involves minimal risk, and the purpose is to identify risk factors and magnitude of risk for developing CA-CDI. Exclusion of pregnant women and children might introduce bias, and the risk factors for these groups are of interest to prevention efforts. We are excluding prisoners because the study required telephone interview and the study objectives can be met without evaluating this vulnerable population.

C. Confidentiality

All individual survey responses and clinical data are confidential. Any published information will be aggregated across the 10 participating sites. All cases will be assigned a unique study identification code. These identification codes will not contain patient identifiers. The link between patient identifiers and the study identification codes will be maintained at each participating EIP site. CDC will only receive coded data and will not be able to link any data back to the study participant. Coded data will be entered into a secure password protected database at the EIP sites. Completed questionnaires and data collection forms will be maintained in secure locations at each EIP site according to local IRB regulations. A limited number of local project personnel will have access to completed forms containing public health information. Personal identifiers, including patient names, address, phone numbers, will be removed from any forms sent to CDC. Within 6 months of the study's completion or according to local IRB regulations,

all copies of the questionnaires containing personal identifiers should be destroyed, eliminating the possibility to link coded data back to study participant.

D. Request for Verbal Consent

EIP sites will obtain information via a phone interview on eligible study subjects. We request written informed consent be replaced with verbal consent. If a case or control participant is deceased, or unable to provide responses during the health interview, a proxy interview with a surrogate (eg. next-of-kin) will *not* occur and the study subject will be ineligible. For all study subjects aged 1-5 years parents or guardians will serve as the proxy. Spanish-speaking case and control patients will be contacted for interview using Spanish-speaking personnel and translated materials. Other non-English speaking subjects will not be interviewed for the study.

Verbal consent (Refer to appendix B) will be obtained from all eligible study subjects or from their parent / legal guardian for child study subjects. Because this study requires that study subjects be interviewed in a timely manner, all study subjects will be interviewed over the telephone. This research presents no more than minimal risk of harm to patients. Only questionnaire data are involved. No procedure for which written consent is normally required outside of the research context is involved. This waiver of written documentation of informed consent will not adversely affect the rights and welfare of study subjects.

The consent will be read to study subjects who agree to the health interview. Some sites may require a consent form with HIPAA language, which has been provided on Appendix B. If required by the local

site, a copy of the consent form with the study participant's response noted and signed by the interviewer, will be kept with each completed questionnaire. Study subjects who agree to the interview will have a copy of the consent form sent to them by United States Postal Service mail immediately after the interview. For the sites that require it, study subjects will also have a copy of the HIPAA/Privacy Notice mailed to their household.

Depending on the local IRBs, it may be required that potential cases and controls (from both vital records department records and phone lists) be sent introduction letters (refer to appendix D) by mail allowing them to call the health department to opt out of being called. Introduction letters will likely delay enrollment of controls in the study, potentially increasing the chances of recall bias. Introduction letters will not be mailed to eligible study participants unless it is required by local EIP sites. In addition, the letter will only have the name of the household member for control participants and not exactly the name of the potential enrollee; hence, reliable responses from the intended participant cannot be guaranteed.

Eight different attempts will be made to reach the potential enrollee on at least 6 different dates. To minimize the chance that attempts will be perceived as a nuisance, project personnel should not call more than twice within a single day nor leave a recorded message at each attempt. When leaving a message, the person will be asked to call back and designate a convenient time for a callback.

When a potential enrollee is successfully contacted via telephone, project personnel will obtain verbal consent for participation. A phone script will be used to aid site personnel when speaking with case- or control-patients (Refer to Appendix A1, pages: 25-26 and 28-29 and A2 pages: 32-33 and 35-36).

Upon completion of the interview, participants will be sent a \$20 gift card as a token of appreciation. The address of the study subject will be confirmed at the end of the interview by EIP staff. CDC will purchase these gift cards and send them to the EIP sites to distribute to the cases and controls who were interviewed. Address information of study participants will not be shared with CDC. This gift card amount is commensurate with time and effort provided by participant and is consistent with what has been provided in other CDC studies involving the same level of time and effort. The amount proposed is not of such a magnitude to interfere with voluntary participation. A Thank You letter with the gift card will be sent to participants (Appendix E).

E. Risks to Study Subjects

The only reasonably foreseeable risk to study subjects is the potential for disclosure of PHI to those other than authorized study personnel. To minimize the risk, all information and identifiers will be kept confidential. Names and personal identifiers will reside at each EIP office and will not be shared with CDC.

There is no penalty for not participating. There is minimal risk to the patient or his or her caretaker, and the only cost is time spent (approximately 30 minutes) being interviewed. Study subjects may refuse to answer any of the questions or stop at any time. This study involves telephone interviews only, and we do not foresee any adverse events other than those related to confidentiality.

There is minimal risk involved and adverse events are not anticipated. Should a breach of confidentiality

occur such that CDC receives personal identifiers, the site would be contacted about this breach in

confidentiality and other sites would be reminded not to send personal identifying information.

F. Benefits to Study Subjects

Although no benefit will be directly conferred to study subjects, data attained from this activity will allow

estimation of the association of proposed risk factors for CA-CDI. This information may lead to public

health measures that can help prevent CA- CDI in the future. There is no penalty for declining to

participate in the study. Study subjects may refuse to answer any of the questions or stop at any time.

VII: **Progress Evaluation**

There will be monthly conference calls between CDC and sites to review results and to discuss study

progress. These conference calls will provide opportunities to discuss data sensitivity, completeness, and

to identify ongoing difficulties. In addition, a the CDI Pathogen Group composed of members from the

EIP sites, the Infectious Disease Society of America, and CDC will oversee the progress of this study. As

sites get closer to reach the study targeted sample size, there will be weekly conference calls to report and

evaluate progress.

VIII. Timeline

August–September 2013: Submit protocol to CDC human subjects review.

October–February 2013: Obtain IRB approvals from local participating institutions.

May 2013–June 2014: OMB approval.

22

March–April 2014: Training of study personnel on data collection.

July 2014–December 2015: Enroll cases and controls, abstract data, perform phone interview and submit data to CDC. (Roll-out will vary by site, estimated 12 months of study/site).

January 2015–May 2015: Analyze data and report findings.

References

- 1. Kuijper EJ, Coignard B, Tull P, et al. Emergence of Clostridium difficile-associated disease in North America and Europe. Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2006;12 Suppl 6:2-18.
- 2. Bartlett JG. Historical Perspectives on Studies of Clostridium difficile and C. difficile Infection. Clinical Infectious Diseases 2008;46:S4-S11.
- 3. Centers for Disease C, Prevention. Severe Clostridium difficile-associated disease in populations previously at low risk--four states, 2005. MMWR Morbidity and mortality weekly report 2005;54:1201-5.
- 4. Centers for Disease C, Prevention. Surveillance for community-associated Clostridium difficile-Connecticut, 2006. MMWR Morbidity and mortality weekly report 2008;57:340-3.
- 5. Kutty PK, Woods CW, Sena AC, et al. Risk factors for and estimated incidence of community-associated Clostridium difficile infection, North Carolina, USA. Emerging infectious diseases 2010;16:197-204.

- 6. Kuntz JL, Chrischilles EA, Pendergast JF, Herwaldt LA, Polgreen PM. Incidence of and risk factors for community-associated Clostridium difficile infection: a nested case-control study. BMC infectious diseases 2011;11:194.
- 7. Karlstrom O, Fryklund B, Tullus K, Burman LG. A prospective nationwide study of Clostridium difficile-associated diarrhea in Sweden. The Swedish C. difficile Study Group. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1998;26:141-5.
- 8. Centers for Disease C, Prevention. Vital signs: preventing Clostridium difficile infections. MMWR Morbidity and mortality weekly report 2012;61:157-62.
- 9. Stevens V, van Wijngaarden E. Proton pump inhibitor use may be associated with an increased risk of Clostridium difficile infection. Evidence-based medicine 2012.
- 10. Chitnis AS, Holzbauer SM, Belflower RM, et al. Epidemiology of Community-Associated Clostridium difficile Infection, 2009 Through 2011. JAMA internal medicine 2013:1-9.
- 11. Sandora TJ, Fung M, Flaherty K, et al. Epidemiology and risk factors for Clostridium difficile infection in children. The Pediatric infectious disease journal 2011;30:580-4

APPENDICES

Appendix A: Adult and Pediatric Case and Control Screening Forms

Public reporting burden of this collection of information is estimated to average 30 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC/ATSDR Information Collection Review Office, 1600 Clifton Road NE, MS D-74, Atlanta, Georgia 30333; ATTN: PRA (0920-0892).

Appendix A1: Adult Case and Control Screening Forms CASE SUBJECT

INITIAL CALL INTRODUCTION

1. [To the person who answers the phone, IF ADULT, otherwise ask to speak to an adult]: "Hello, my name is
I am calling from the [State health dept.]. May I please speak to [Potential enrollee]?"
Yes: person who answered is potential enrollee; [go to case patient call script]
Yes: coming to the phone; [go to case patient call script]
No: person is unavailable – record call back time on phone log if given
No: person is deceased: -STOP- CASE INELGIBLE SAY:
"I would like to offer my condolences and apologize for any inconvenience that this call may have
caused to you. Thank you for your time
No: person is incapacitated; -STOP- CASE INELGIBLE SAY:
"Thank you for your time. Have a nice day"
Does not speak English; [record language in comment section of phone log.]
- IF CDANICH CDFAKING, "May will true to call be all with company who appeles

- IF SPANISH SPEAKING: "We will try to call back with someone who speaks Spanish, thank you."
- IF OTHER LANGUAGE: "Thank you for your time. Have a nice day" [If case speaks a language other than English or Spanish, he/she is not eligible. Record on tracking log as "No English or Spanish." =stop=]

CASE PARTICIPANTS Call Script:

"I am calling on behalf of the Centers for Disease Control and Prevention (CDC) and the [State Health Dept.] because you may be eligible to participate in a public health study. This study is being performed by CDC and your State Health Department. We are calling you because you had an infection with a germ called Clostridium

difficile; sometimes it is also called <i>C. diff</i> . The <state department="" health=""> routinely tracks how often people in your area get sick from <i>C.difficile</i> infections and is notified whenever a person develops this infection.</state>
Participation is voluntary and involves completing a 30 minute interview over the phone. It will include
questions about your illness, healthcare visits, medical history, and recent medications. Please know that your
answers will be kept secure and you may choose not to answer any question. If you agree to participate we will
send you a \$20 gift card as a token of appreciation. May I tell you more about the study?"
Yes; [go to CASE SCREENING
No; [go to Q3]
3. "Your participation in this study is very important. We are trying to better understand why people develop
Clostridium difficile infection. May I schedule a time to talk that would be better for you?"
Yes; [<u>Record day/time on Phone Log</u>].
 "Thank you very much for your time, I will call you back later."[=STOP=and call the
person back at the requested day/time.]
No;
 "Sorry to have disturbed you. Good-bye." [=STOP=and record in the interview
tracking log as "Refused to participate."]
******BEFORE YOU PROCEED, HAVE A CALENDAR IN FRONT OF YOU*****
CASE SUBJECT SCREENING QUESTIONS
I will ask you questions about your illness, healthcare contacts, household contacts, other exposures and medical history. It may be difficult to remember, but I would like your best guess for each question.
Because I will be asking about specific dates around the time your illness began, it may be helpful for you
to have a calendar or datebook in front of you. I can hold while you get these things. The dates we are
interested in are between [12 weeks <i>before</i> positive_specimen collection Date/] to
[positive specimen collection date/]. When Participant returns say "I would like to begin
with a few questions to be sure you are eligible to participate in the study"
Have you ever been diagnosed with <i>C. difficile before</i> the collection of your stool specimen on [specimen collection date/]? Yes1
(If Yes –STOP Interview and say: "We are only interviewing people who have not had a previous C. difficle diagnosis. Thank you for your time")
No2 Don't know/Not sure 7

Refused	i	9)					
specimen c] Yes (If Yes	ollection date	/ 1 rview and s	_/]? ay "We are	only intervie		e in the 12 we		
No		2	(Go to Q.3))				
Don't kr	now/Not sure	7	,					
(If Don'	l t know/ Refu spital during	se- STOP In	iterview and			viewing peopl	le who c	lid not stay
						pecimen colle a 24 hour per		
Yes		1	(Go to Q. 3	A)				
Don't kr Refused (IF No	now/Not sure d o, Don't know nea with their		,) TOP Intervie			interviewing)	people	who had
	No date.) Don't know/N date.)	ot sure	1 (If) 2 (fill 7 (fill	Yes –fill in da in date of sp in date of sp	ate diarrhea pecimen coll pecimen coll	began and us lection and us lection and us lection and us	se as rei	ference ference
		€ REFER	RENCE DATI	E:/ (mm/dd/yy				
		 			2 w	veek before	/	, !
		 				eks before		
		i I I				eeks before		1
		1 1 1						!

<u>CASE CONSENT SCRIPT</u>: GO TO CASE CONSENT AND SAY "Now that I know you are eligible to participate, I would like to share some additional details about the study and obtain your

verbal permission for participation. Feel free to stop me and ask questions at any time." [AFTER CONSENT COMPLETE CONTINUE WITH INTERVIEW SECTION 1]

CONTROL SUBJECTS INITIAL CALL INTRODUCTION

1. [To the person who answers the phone, IF ADULT, otherwise ask to speak to an adult]: "Hello, my name is
I am calling from the [State health dept.]. I am calling about a public health study on an infection
called Clostridium difficile. For this study we are looking for people who are [insert sex / age group:
]. Is there anyone in your household in this group who I can speak with?"
Yes: person who answered is a potential enrollee; [go to control patient call script]
Yes: coming to the phone; [go to control patient call script]
No: person is unavailable – record call back time on phone log if given
No: person is deceased: -STOP- CONTROL INELGIBLE SAY:
"I would like to offer my condolences and apologize for any inconvenience that this call may have
caused to you. Thank you for your time."
No: person is incapacitated; -STOP- CONTROL INELGIBLE SAY:
"Thank you for your time"
Does not speak English; [record language in comment section of phone log.]
 IF SPANISH SPEAKING: "We will try to call back with someone who speaks

- Spanish, thank you." ■ IF OTHER LANGUAGE: "Thank you for your time. Have a nice day" [If control speaks
- a language other than English or Spanish, he/she is not eligible. Record on tracking log as "No English or Spanish." =stop=]

Control Participants Call Script

"I am calling on behalf of the Centers for Disease Control and Prevention (CDC) and the [State Health Dept.] because you may be eligible to participate in a public health study. This study looks at how people living in the community get an illness caused by a germ called *Clostridium difficile* (also called *C. diff*). As part of our study, d

, 3	, ,	`	, ,	,
we need to talk to people	who did not become ill with	C.diff, but live in the same	e area as some	one who did an
who is around the same a	age as the ill person. Participa	ation is voluntary and invo	lves completing	a 30 minute
interview over the phone.	. It will include questions abo	ut your healthcare visits, r	medical history,	and recent
medications. Please kno	w that your answers will be k	ept secure and you may c	hoose not to an	swer any
question. If you agree to	participate we will send you a	a \$20 gift card as a token	of appreciation.	May I tell you
more about the study?"				
Yes; [<u>go to CONTRC</u> No; [<u>go to Q 2]</u> .	DL SCREENING]			

2. "Your participation in this study is very important. We are trying to better understand why people develop
Clostridium difficile infection. May I schedule a time to talk that would be better for you?"
Yes; [Record day/time on Phone Log].
 "Thank you very much for your time."[=STOP= and call back at requested day and
time.]
No;
"Sorry to have disturbed you. Good-bye." [=STOP= and record on interview tracking
log as "Refused to participate."]
ing as included to participate.
******BEFORE YOU PROCEED, HAVE A CALENDAR IN FRONT OF YOU*****
Control Subject Screening Questions
Control Subject Screening Questions
I will ask you questions about your healthcare contacts, household contacts, other exposures and medical
history. It may be difficult to remember, but I would like your best guess for each question. Because I will
be asking about specific dates, it may be helpful for you to have a calendar or datebook in front of you. The
dates we are interested in are between [12 weeks <u>before</u> Matched CASE participant's Reference
Date/] to [matched case participant's Reference Date/]. I can hold
while you get these things. Do you need a minute to go get any of these items?
When Participant returns say "I would like to begin with a few questions to be sure you are eligible to
participate in the study"
participate in the Study
1. Were you between the ages of [matched case patient age group] on [REFERENCE Date
Yes1 (Go to Q.2)
res (Go to Q.2)
No2
Don't know/Not sure
(If No, Don't know / Refuse STOP Interview and say:" We are only interviewing patients in that age
group. Thank you for your time".)
2. Did you live in [EIP catchment area counties] on [REFERENCE Date/
Yes (Go to Q.3)
No2
Don't know/Not sure7
Refused9 (If No, Don't know / Refuse STOP Interview and say:" We are only interviewing patients who lived in

3. Did y	ou stay overnight in a hospital, long term care facility, or nursing home in the 12 weeks <i>before</i>
[REFEF	RENCE Date/]?
	Yes
	No2 (Go to Q.4)
stay in	Don't know/Not sure
4. Had <u>y</u>	you ever been diagnosed with <i>C. difficile</i> before [REFERENCE date//]? Yes1 (If Yes –STOP Interview and say: "We are only interviewing people who have not had a previous <i>C. difficle diagnosis. Thank you for your time.</i>)
	No2 (Go to Q.5)
	Don't know/Not sure
	//]? We define diarrhea as 3 or more loose stools in a 24 hour period. Yes1
	(IF YES- STOP Interview and say "We are only interviewing people who did not have diarrhea. Thank you for your time.)
	No2 (GO TO CONTROL CONSENT SCRIPT BELOW)
have	Don't know/Not sure
CONTI	ROL CONSENT SCRIPT: GO TO CONTROL CONSENT AND SAY "Now that I know you are
eligible	e to participate, I would like to share some additional details about the study and obtain
	erbal permission for participation. Feel free to stop me and ask questions at any time." ER CONSENT COMPLETE CONTINUE WITH INTERVIEW SECTION 1]

APPENDIX A2: Pediatric Case and Control Screening Forms CASE SUBJECT

INITIAL CALL INTRODUCTION

-	wers the phone, IF ADULT, otherwise ask to speak to an adult]: "Hello, my name is om the [State health dept.]. May I please speak to [parent/ guardian of potential
enrollee]?"	
Yes: person who answ	ered is parent or guardian of enrollee; [go to case patient call script]
Yes: coming to the pho	one; [go to case patient call script]
No: person is unavailal	ole – record call back time on phone log if given
•	h; [record language in comment section of phone log.] IF SPANISH SPEAKING: "We will try to call back with someone who speaks Spanish, thank you." IF OTHER LANGUAGE: "Thank you for your time. Have a nice day" [If case speaks a language other than English or Spanish, he/she is not eligible. Record on tracking log as "No English or Spanish." =stop=]
CASE PARTICIPANTS Ca	all Script:
2. "I am calling on behalf o	f the Centers for Disease Control and Prevention (CDC) and the [State Health Dept.]
because your child may be	e eligible to participate in a public health study. This study is being performed by CDC
and your State Health Dep	artment. We are calling you because your child had an infection with a germ called
	imes it is also called <i>C. diff</i> . The <state department="" health=""> routinely tracks how often</state>
	k from <i>C.difficile</i> infections and is notified whenever a person develops this infection.
•	nd involves completing a 30 minute interview over the phone. It will include
•	's illness, healthcare visits, medical history, and recent medications. Please know
•	ept secure and you may choose not to answer any question. If you agree to u a \$20 gift card as a token of appreciation. May I tell you more about the study?"
Yes; [go to Case Subje	ect Screening]
No; [go to Q3]	
·	s study is very important. We are trying to better understand why people develop
Clostridium difficile infection	n. May I schedule a time to talk that would be better for you?"
Yes; [<u>Record</u>	day/time on Phone Log].

 "Thank you very much for your time, I will call you back later."[=STOP=and call the
person back at the requested day/time.]
No;
 "Sorry to have disturbed you. Good-bye." [=STOP=and record in the interview
tracking log as "Refused to participate."]
*******BEFORE YOU PROCEED INTERVIEW, HAVE A CALENDAR IN FRONT OF YOU******
CASE SUBJECT SCREENING QUESTIONS
will ask you questions about your child's illness, healthcare contacts, household contacts, other
exposures, and medical history. It may be difficult to remember, but I would like your best guess for each
question. Because I will be asking about specific dates around the time your child's illness began, it may b
nelpful for you to have a calendar or datebook in front of you. I can hold while you get these things. The
dates we are interested in are between [12 weeks <u>before</u> positive_specimen collection
Date/] to [positive specimen collection date/]. Do you need a minute
to go get any of these items?
When Participant returns say "I would like to begin with a few questions to be sure you are eligible to
participate in the study"
1. Today, what is your child's health status? I will read some choices:
Well1
ll or sick
feceased " If deceased say : "I would like to offer my condolences and apologize for any inconvenience that this cal
may have caused to you and we do not need to continue with the interview. Thank you for your time."
Don't know/Not sure7
Refused9
f Don't know / refused say "We are only interviewing parents if the child's health status is known. Thank
you for your time"
2. Has your child been diagnosed with <i>C. difficile before</i> the collection of your child's stool specimen on [specimen
collection date/]?
Yes(If Yes –STOP Interview and say "We are only interviewing people who have not had a previous C
difficle diagnosis. Thank you for your time.)
No2 Don't know/Not sure7
Refused9

B. Did your child stay Reference Date	overnight in a hospital, long term care facility, or nursing hor	ne in the 12 wee	eks <i>before</i>
Yes	_'' 1		
(If Yes -STOP	Interview and say "We are only interviewing people who e." Thank you for your time.)	did not stay ir	n a hospital
Don't know/Not si			
Refused			
date/ Yes No Don't know/Not st Refused (IF NO, DON'T	ıre7	a 24 hour period	I.
Yes No date.) Don't kno date.)	ember when your child's diarrhea began?	on and use as ro on and use as ro on and use as ro	eference eference eference
	€ REFERENCE DATE://		
	2 week t	pefore/_	/ !
	4 weeks t	pefore/_	/ :
	•	oefore/_	1

GO TO CASE CONSENT AND SAY "Now that I know you are eligible to participate, I would like to share some additional details about the study and obtain your verbal permission for participation. Feel free to stop me and ask questions at any time." [AFTER CONSENT COMPLETE CONTINUE WITH INTERVIEW]

CONTROL SUBJECTS INITIAL CALL INTRODUCTION

1. [To the person who answers the phone, IF ADULT, otherwise ask to speak to an adult:] "Hello, my name is I am calling from the [State health dept.]. I am calling about a public health study on an infection called Clostridium difficile. For this study we are looking for children who are [insert sex / age group]. Is there a parent or guardian of a child in this group who I can speak with?"
Yes: coming to the phone; [go to control patient call script]
No: person is unavailable – record call back time on phone log if given
Does not speak English; [record language in comment section of phone log.]
 IF SPANISH SPEAKING: "We will try to call back with someone who speaks
Spanish, thank you."
 IF OTHER LANGUAGE: "Thank you for your time. Have a nice day" [If control speaks
a language other than English or Spanish, he/she is not eligible. Record on tracking
log as "No English or Spanish." =stop=]
2. "I am calling on behalf of the Centers for Disease Control and Prevention (CDC) and the [State Health Dept.] because your child may be eligible to participate in a public health study. This study looks at how people living in the community get an illness caused by a germ called Clostridium difficile (also called C. diff). As part of our study, we need to talk to the parents of children who did not become ill with C.diff, but live in the same area as
someone who did and who is around the same age as the ill person. The study is voluntary and involves
completing a 30 minute interview over the phone. It will include questions about your child's healthcare visits,
medical history, and recent medications. Please know that your answers will be kept secure and you may
choose not to answer any question. If you agree to participate we will send you a \$20 gift card as a token of
appreciation. May I tell you more about the study?"
Yes; [<u>go to CONTROL SCREENING QUESTIONS]</u> No; [<u>go to Q 3]</u> .
3. "Your participation in this study is very important. We are trying to better understand why people develop
Clostridium difficile infection. May I schedule a time to talk that would be better for you?"
Yes; [Record day/time on Phone Log].
"Thank you very much for your time."[=STOP= and call back at requested day and

time.]

No:
INU,

• "Sorry to have disturbed you. Good-bye." [=STOP= and record on interview tracking log as "Refused to participate."]

******BEFORE YOU PROCEED, HAVE A CALENDAR IN FRONT OF YOU*****

Control Subject Screening Questions

I will ask you questions about your child's healthcare contacts, household contacts, other exposures, and
medical history. It may be difficult to remember, but I would like your best guess for each question.
Because I will be asking about specific dates, it may be helpful for you to have a calendar or datebook in
front of you. The dates we are interested in are between [12 weeks before Matched CASE participant's
Reference Date
can hold while you get these things. Do you need a minute to go get any of these items?
When Participant returns say "I would like to begin with a few questions to be sure you are eligible to
participate in the study"
1. Today, what is your child's health status? I will read some choices:
Well1
Ill or sick2
Deceased5 "If deceased say: "I would like to offer my condolences and apologize for any inconvenience that this call
may have caused to you and we do not need to continue with the interview. Thank you for your time."
Don't know/Not sure7
Refused9
If Don't know / refused say "We are only interviewing parents if the child's health status is known. Thank
you for your time"
Was your child between the ages of [matched case patient age group] on [REFERENCE Date
/
Yes1 (Go to Q.2)
No2
Don't know/Not sure7
Refused9
(If No, Don't know / Refuse STOP Interview and say:" We are only interviewing patients in that age
group. Thank you for your time".)
2. Did years shild live in IEID cots broads are countied as IDEEEDENCE Date.
2. Did your child live in [EIP catchment area counties] on [REFERENCE Date/]?
Yes1 (Go to Q.3)
No2
Don't know/Not sure7 Refused9
REUSEL 9

(If No, Don't know / Refuse STOP Interview and say:" We are only interviewing patients who lived in that area. Thank you for your time".)

3. Did	your child stay overnight in a hospital, long term care facility, or nursing home in the 12 weeks <i>before</i>
[Refere	ence Date/
	Yes1
	(If Yes –STOP Interview and say "We are only interviewing people who did not stay in a hospital
	during that time." Thank you for your time.) No
	Don't know/Not sure7
	Refused9
	(If Don't know / Refuse STOP Interview and say "We are only interviewing people who did not
ctav in	a hospital during that time. Thank you for your time")
Stay III	a nospital during that time. Thank you for your time j
4 Hac	your shild over been diagnosed with C. difficile in the past?
4. nas	your child ever been diagnosed with <i>C. difficile</i> in the past?
	Yes
	difficle diagnosis. Thank you for your time.)
	No
	Don't know/Not sure
	Refused9
	(If Don't know / Refuse STOP Interview and say "We are only interviewing people who did not
have C	C. difficile in the past. Thank you for your time")
nave C	unitale in the past. Thank you for your time j
5 Did v	your child have diarrhea within the 12-weeks before [REFERENCE date/]? We define
	ea as 3 or more loose stools in a 24 hour period.
0.100.1110	Yes1
	(IF YES- STOP Interview and say "We are only interviewing people who did not have diarrhea.
	Thank you for your time.)
	No2 (GO TO CONSENT SCRIPT BELOW)
	Don't know/Not sure7
	Refused9
	(If Don't know / Refuse STOP Interview and say "We are only interviewing people who did not
have	diarrhea. Thank you for your time")

<u>CONTROL CONSENT SCRIPT</u>: GO TO CONTROL CONSENT AND SAY "Now that I know you are eligible to participate, I would like to share some additional details about the study and obtain your verbal permission for participation. Feel free to stop me and ask questions at any time."

[AFTER CONSENT COMPLETE CONTINUE WITH INTERVIEW]

APPENDIX B: VERBAL CONSENT FOR PARTICIPATION WITH AND WITHOUT HIPPA LANGUAGE VERBAL CONSENT FOR PARTICIPATION IN A RESEARCH PROJECT (Non-HIPPA language)

Study Title: Commu	nunity- Associated <i>Clostridium difficile</i> Risk Factor Study	
Principal Investigat	ator:	
Funding Source: (S	(State Department of Public Health); Centers for Disease Control and	Prevention

Invitation to Participate and Description of Project

We are asking you to take part in an assessment to look at how people get infections with *Clostridium difficile*, a germ that can make people sick with diarrhea and might put them in the hospital. This study is being conducted by staff at <state health department>in conjunction with the Centers for Disease Control and Prevention (CDC). These infections are very important. We are doing this study to try to learn more about where they come from and how to prevent them.

We are contacting you to ask [you to participate / you to participate on your child's behalf] because [you/your child] or someone who lives in your area had this infection.

Procedures

The <state health department> routinely tracks how often people in your area get sick from *C.difficile* infections and is notified whenever a person develops this infection. Your medical doctor is required to report cases of *C. difficile* to the state health department. If you agree to take part in this study we will ask you to complete a survey over the phone. To understand where these infections come from and how they can be prevented we need to talk to people who got sick **and** to people who **did not** get sick. We will ask both groups about [your/your child's] healthcare, household, medications, and about the types of food [you/ your child] eat(s).

The interview will take about 30 minutes. You can refuse to answer any of the questions. You are free to not participate, if you don't want to.

Risks and Inconveniences

There are no risks to you for being in this research study, other than the possibility that some questions may be uncomfortable or difficult to answer. There are no direct benefits to you for joining this study. There is no penalty for not being in this study. You do not have to answer any questions you are uncomfortable with. You may stop at any time. After your participation in the study, we will send you a \$20 gift card to show our appreciation for your time and effort.

Security of Information

All we learn about [you/ your child] and your family will be kept private as much as the law allows. We will only use information grouped with information from many other participants, without using names or other personal information. Any information collected that could identify your child will be destroyed when the evaluation is done.

Voluntariness and Withdrawal

You are free to choose not to tak	e part in this study. Refusing to take part will not affect any me	dical care or
benefits [you/your child] receive.	If you decide later that you want to stop, you should write to (st	ate Principal
Investigator)	at the following address:	If you choose to
withdraw from the study, the data	collected in this interview will be destroyed and removed from a	ıny database
associated with this project. You	can also refuse to answer any questions or stop the interview a	at any time.

Questions

If you have questions about this study or you feel you may have been harmed by this study, you may call the <<u>EIP</u> <u>site</u>> at <<u>contact number</u>>.

If you have further questions about this project or if you have a research-related problem, you may contact the Principal Investigator, <name of EIP CDI investigator and contact number>. If you have any questions about your rights as a research subject, you may contact the <name and contact number to the Chair of the local IRB or Research Ethics, etc>.

If you feel you have been harmed in any way by taking part of this study, or if you have questions about your rights, you may also contact CDC's Human Research Protection Office at 1-800-584-8814; leave a message with your name, phone number, and refer to CDC protocol #XXXX and someone will call you back.

Now that I have told you about the study, do you have any questions for me about the study? (Answer all questions

Authorization

MATCHED CASE PATIENT ID: _____

before proceeding to next question)	
that makes you uncomfortable"	f your child)? (Verbal consent given) Now I will ask you some questions. You may refuse to answer any question or you time. If you change your mind please call me at: (_)
Name of Subject	
Name of Parent/Guardian	
Interviewer signature	Date
I will be happy to mail a copy of this con: (Record mailing information separately)	sent form as well as information about <i>C. diff</i> infection if you would like.

VERBAL CONSENT FOR PARTICIPATION IN A RESEARCH PROJECT HIPPA LANGUAGE VERSION

Study Title: Community- Associated Clostridium difficile Risk Factor Study
Principal Investigator:
Funding Source: (State Department of Public Health); Centers for Disease Control and Prevention

Invitation to Participate and Description of Project

We are asking you to take part in an assessment to look at how people get infections with *Clostridium difficile*, a germ that can make people sick with diarrhea and might put them in the hospital. This study is being conducted by staff at <state health department>in conjunction with the Centers for Disease Control and Prevention (CDC). These infections are very important. We are doing this study to try to learn more about where they come from and how to prevent them.

We are contacting you to ask [you to participate / you to participate on your child's behalf] because [you/your child] or someone who lives in your area had this infection.

Procedures

The <state health department> routinely tracks how often people in your area get sick from *C.difficile* infections and is notified whenever a person develops this infection. Your medical doctor is required to report cases of *C. difficile* to the state health department If you agree to take part in this study we will ask you to complete a survey over the phone. To understand where these infections come from and how they can be prevented we need to talk to people who got sick **and** to people who **did not** get sick. We will ask both groups about [your/your child's] healthcare, household, medications, and about the types of food [you/ your child] eat(s).

The interview will take about 30 minutes. You can refuse to answer any of the questions. You are free to not participate, if you don't want to.

Risks and Inconveniences

There are no risks to you for being in this research study, other than the possibility that some questions may be uncomfortable or difficult to answer. There are no direct benefits to you for joining this study. There is no penalty for not being in this study. You do not have to answer any questions you are uncomfortable with. You may stop at any time. After your participation in the study, we will send you a \$20 gift card to show our appreciation for your time and effort.

Security of Information

All we learn about [you/ your child] and your family will be kept private as much as the law allows. We will only use information grouped with information from many other participants, without using names or other personal information. Any information collected that could identify your child will be destroyed when the evaluation is done. **HIPAA Authorization**

While we will make every effort to keep what we learn about you private, this cannot be guaranteed. Results of the research may be presented at meetings or in publications, but your name will not be used. The Federal Health Insurance Portability and Accountability Act (HIPAA) requires us to get your permission to use health information collected as part of research. This permission is called an Authorization. We will use information we collect about [you/your child] including information from the survey such as exposures and demographics [and information about your/ your child's illness]. If you decide to take part, the Authorization for this study will not expire unless you cancel (revoke) it. The information collected will be kept until the study is completed and all

data is analyzed and presented/published. You can always cancel by writing to the (study investigator). If you cancel your Authorization, you will also be removed from the study. By giving consent, you give us permission to use and/or share your health information.

Voluntariness	and	Withdrawal

(Record mailing information separately)

You are free to choose not to take part in this study. Refusing to take part will not affect any medical care or benefits [you/your child] receive. If you decide later that you want to stop, you should write to (state Principal Investigator) at the following address:If you choose to withdraw from the study, the data collected in this interview will be destroyed and removed from any database associated with this project. You can also refuse to answer any questions or stop the interview at any time.	
<u>Questions</u>	
If you have questions about this study or you feel you may have been harmed by this study, you may call the < <u>El</u> <u>site></u> at < <u>contact number></u> .	<u>P</u>
If you have further questions about this project or if you have a research-related problem, you may contact the Principal Investigator, <name and="" cdi="" contact="" eip="" investigator="" number="" of="">. If you have any questions about your rights as a research subject, you may contact the <name and="" chair="" contact="" etc="" ethics,="" irb="" local="" number="" of="" or="" research="" the="" to="">.</name></name>	
If you feel you have been harmed in any way by taking part of this study, or if you have questions about your rights you may also contact CDC's Human Research Protection Office at 1-800-584-8814; leave a message with your name, phone number, and refer to CDC protocol #XXXX and someone will call you back.	,
<u>Authorization</u>	
Now that I have told you about the study, do you have any questions for me about the study? (Answer all questions before proceeding to next question)	}
Do you agree to participate (on behalf of your child)? (Verbal consent given) YesIF YES-> say "Thank you. Now I will ask you some questions. You may refuse to answer any question that makes you uncomfortable" No IF NO-> say "Thank you for you time. If you change your mind please call me at: (_)	า
Name of Subject	
Name of Parent/Guardian	
Interviewer signatureDate	

I will be happy to mail a copy of this consent form as well as information about *C. diff* infection if you would like.

MATCHED CASE PATIENT ID:

€ CASE € CONTROL Patient ID:	State ID:				
REFERENCE Date//	-				
APPENDIX C: ADULT AND PEDIATRIC QUESTONAIRRES					

Public reporting burden of this collection of information is estimated to average 30 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC/ATSDR Information Collection Review Office, 1600 Clifton Road NE, MS D-74, Atlanta, Georgia 30333; ATTN: PRA (0920-0892).

APPENDIX C1: COMMUNITY ASSOCIATED CLOSTRIDIUM DIFFICILE ADULT CASE AND CONTROL INTERVIEW

SECTION 1: IDENTIFIERS- CASES AND CONTROLS

1. € CASE € CONTROL 2. Study ID:			
3. Reference date:// (mm/dd/yyyy)			·
2 week before	/_	/	¦
4 weeks before	/_	/	:
12 weeks before	/	/	
4. Age (years) €€€			
5. Sex € Male € Female			
5. Sex & Ividie & Female			

SECTION 2: ILLNESS QUESTIONS- ********CASES ONLY ****CONTROLS SKIP TO SECTION 3, Q. 10*********

Now I will ask you questions about your illness.

€ CASE € CONTROL Patient ID: State ID: REFERENCE Date//
6. How many days did your diarrhea last? €€€
Don't know/Not sure7
Refused9
6A. On the worst day of your diarrhea, what was the approximate number of stools you had in a 24-hour period? ≥3-<5 stools
7. Did you have any of the following symptoms associated with your <i>C. difficile</i> illness? [READ LIST] Yes No DK/NS Refused Bloody stools 1 2 7 9 Fever 1 2 7 9 Nausea 1 2 7 9 Vomiting 1 2 7 9 Abdominal pain 1 2 7 9 Other 1 2 Specify:
8. Were you hospitalized overnight for your <i>C. difficile</i> illness? Yes
9. At the time of your <i>C. difficile</i> diagnosis, were you told by a doctor or healthcare provider that you had any other stomach [enteric, gastrointestinal] infection? Yes

Yes No DK/NS

Refused

[Read list if necessary]

Patient ID:	€ CONTROL	State ID:				
REFERENCE	(mm/dd/yyyy)					
	Campylobacter	1	2	7	9	
	E. coli	1	2	7	9	
	Listeria	1	2	7	9	
	Salmonella	1	2	7	9	
	Shigella	1	2	7	9	
	Vibrio	1	2	7	9	
	Yersinia	1	2	7	9	
	Cryptosporidium	1	2	7	9	
	Giardia	1	2	7	9	
	Rotavirus	1	2	7	9	
	Norovirus	1	2	7	9	
	Other	1	2			
	Specify:					

SECTION 3: HEALTHCARE CONTACTS- CASES AND CONTROLS

Now I will ask you questions a	about your healthcare contacts between [12 weeks <u>before</u> Referenc
Date/] to [Re	eference Date/].
10. Did you receive care in any dod	ctor's office, dental office, hospital, or any other medical facility in the 12 weeks
before [REFERENCE DATE	
Yes	1
No	2 (Go to Q.11)
Don't know/Not sure	7 (Go to O 11)

€ CASE	€ CONTROL		
Patient ID:		State ID:	
REFERENCE	Date / /		
	(mm/dd/vvvv)		

[READ LIST]	YES=1	NO=2	DN/ NS=7	Refuse=9	If yes, How many weeks prior to (Reference				
			110 /		I	//	\ did		
						this place?			
					2 weeks	4 weeks	12 weeks		
A 1 1 /									
Ambulatory /									
Outpatient									
procedure center									
Ambulatory /									
Outpatient									
Surgery center									
Dental office									
Doctor's office									
ED									
Hemodialysis									
Hospital									
Outpatient lab									
Physical									
Therapy Center									
Urgent Care									
Other									

IF NO TO ALL OPTIONS IN Q.10A then SKIP to Q.11

€ CASE € CONTROL	
Patient ID:	State ID:
REFERENCE Date//	
(mm/dd/yyyy)	
10B. during those visits in the 12 weeks	before (Reference Date/) did you have any of the
following procedures performed?	
*****If Subject answered YES to dental v	isits only in 10A then only ask about last two items (oral surgery and dental
cleaning)******	

[READ LIST]	YES=1	NO=2	DN/NS=7	Refuse=9	If yes, Hor (Reference did this pr	eks prior to	
					2 weeks	4 weeks	12 weeks
Upper Endoscopy (Did the doctors pass a tube through							
your mouth or nose into your stomach?)							
Colonoscopy or Sigmoidoscopy (Did the doctors pass a tube into your rectum to look into your							
colon/bowel?) X-ray that required GI Prep (Did you have an X-ray performed where you had to swallow something first?)							
Chemotherapy Surgery in an operating room as an outpatient If yes, Specify type:							
Other Medical							

€ CASE € CONT Patient ID: REFERENCE Date	FROL	State ID:			
Procedure:					
Oral Surgery					
Dental Cleaning					
NoDon't know/No Refused 11A. What typ	the 12 weeks but	efore [Reference Da	ate//_]?	

€ CASE €	CONTROL							
Patient ID:			State ID:			_		
REFERENCE Date	e/_ (mm/dd/yyyy)	/						
	(IIIII/dd/yyyy)	'						
[READ LIST]	YES=1	NO=2	DN/NS=7	Refuse=9	If ves H	ow many w	veeks	SECTION
	ILS-I	110-2	D 11/113-7	Keruse-5	prior to (-	VCCKS	
					_	/ <u>/</u> /	\ did	<u>4:</u>
						this place?		
					2 weeks	4 weeks	12	_
					2 weeks	4 weeks		
							weeks	
Ambulatory /								-
Outpatient								
procedure cente	ar l							
Ambulatory /	:1							-
Outpatient								
Surgery center								-
Dental office								-
Doctor's office								
ED								
Hemodialysis								
Hospital								
Long term care	/							
skilled nursing								
facility								
Outpatient lab								-
Physical								-
Therapy Center								
Urgent Care								_
								-
Other								
]
HOUSEHOLD CO	NTACTS							
The next few q	uestions a	re about	you and pe	ersons who	lived with	you durin	g the 12 w	eeks before
[Reference Da	to I	,	1			_		
_			=			_		
12. How many pe	anla livad in	vour hou	cohold includi	na vourcelf d	uring that tin	~~? € . "	i ancwar ic	ana (cubiaat
		your nous	seriola iriciaal	ng yoursen a	uring that tir	ne? • II	answer is c	me (Subject
lives alone) skip	to Q.19							
12A Hov	w many hous	ehold me	mbers, not inc	cludina vourse	elf were in e	ach of these	age groups	2 [List
	of people in			sidding youro	J. 11010 III 0		, ago groupe	. [=.01
		_		$\boldsymbol{\varsigma}$	\triangle	_	<u>-</u>	$\boldsymbol{\mathcal{L}}$
Ages	ヒ<1 モ	1 to 3	€4 to 10	= 11 to 1	L7 = 18	3 to 34	35 to 59	€ 60+
10 Did om - harra	obold!-	or ovolval	na va = lf	oor diamazzo	المماريطانية	dulta in alia	oro)	
13. Did any hous	enoia memb Yes			ear diapers?	(including a	uuits in diap	ers)	
	Vo							
	Don't know/N							
	Refused							

€ CASE € Patient ID: REFERENCE Da	CONTROL ate/		D:			
daycare? We c	onsider dayca er week under Yes No Don't know/N Refused	re to be any place an adult's care wi	inside or outs th at least two 1 2 (Skip to Q 7 (Skip to Q 9 (Skip to Q	15) 15) ded daycare and wh	e a household me ho did not live with	mber spends at n you
AGE Group				Daycare Setting	1	
	Home	Center	Nanny	Other (specify)	Don't know	Refused
< 1	1	2	3	(3) 33 77	7	9
1 to 3	1	2	3		7	9
4 to 10	1	2	3		7	9
11 to 17	1	2	3		7	9
18 to 34	1	2	3		7	9
35 to 59	1	2	3		7	9
60 +	1	2	3		7	9
15. In the 12 we hospital?	er- care is proving / care proving /	der share- two or mber either full-time either full-time eference Date	commercial b more families ne or part-time	uilding with many pr have a single nann	y / care provider to	take care of
No Don't k Refuse	now/Not sure. d	2 7 9	_!!	_)], did any househ	old member stay c	overnight in a

_/___/___)], did anyone else in your household have diarrhea?

17. In the 12 weeks before [Reference Date_

€ CAS		Ctata ID:						
Patient I	ENCE Date / /	State ID:						
IXEL EIXI	(mm/dd/yyyy)							
	Yes							
	No							
	Don't know/Not sure							
	Refused	9 (Go to Q.18)						
	17A. <i>If yes</i> , did you assist this pe	erson with toilet	ing (i	includi	ng diaper	changes)	?	
	Yes							
	No	2						
	Don't know/Not sure	7						
	Refused	9						
	17B. Was this person diagnosed	with C. difficile	?					
	Yes							
	No	2						
	Don't know/Not sure	7						
	Refused							
18. Did	any of your household members	work or volunte	er. ir	n anv d	capacity, a	at a hospita	al. other medi	cal facility, or in
	ility where patient care is provided							
,	Yes			•				
	No							
	Don't know/Not sure							
	Refused							
		s (55 to Q .=5)						
	18A. If yes, what type of healthc	are setting?						
	(READ LIST)	-	es/	No	DK/NS	Refused		
	Hospital		1	2	7	9		
	Emergency department		1	2	7	9		
	Doctor's office		1	2	7	9		
			1	2	7			
	Dentist	uroina facilita	_			9		
	Long term care (skilled r	ursing facility)	1	2	7	9		
	Hemodialysis facility		1	2	7	9		
	Other facility		1	2				
	Specify:							

€ CASE Patient ID:	€ CONTROL State ID:					
REFEREN	CE Date State ID: (mm/dd/yyyy)					
	BB. Did their job involve direct physical contacter get out of a chair	ct with	n the p	atients? F	or example, touching the patient	t to help
110	Yes1					
	No2 (Go					
	Don't know/Not sure7 (Go					
	Refused9 (Go	to Q.	.19)			
	18B1. <i>If yes,</i> what was their main job?	1				
	18B2. Joh Code €€-	€€	€	E (Fil	I in job code after interview is	
	finished)			(, ,,	inifes ocae and interview is	
	ou work or volunteer, in any capacity, at a hos ovided in the 12 weeks before [Reference Da					ient
	es1					
	0					
Ri	on't know/Not sure7 (Go to Q.20 efused 9 (Go to Q.20))))				
19	9A. <i>If yes,</i> what type of healthcare setting?	\/	NI-	DI//NC	Dafting d	
	(READ LIST) Hospital	Yes 1	No 2	DK/NS 7	Refused 9	
	Emergency department	1		7	9	
	Doctor's office	1	2	7	9	
	Dentist	1	2	7 7	9	
	Long term care (skilled nursing facility)		2	7	9	
	Hemodialysis facility Other facility	1 1	2 2	7	9	
	Specify:			· · · · · · · · · · · · · · · · · · ·		
	_					
	9B. Did your job involve direct physical contact er get out of a chair	ct with	n the p	atients? F	or example, touching the patient	t to help
	Yes1					
	No					
	Don't know/Not sure7 (Go Refused9 (Go					
	19B1. <i>If yes,</i> what was your main job?)				
						

€ CASE €	€ CONTROL
Patient ID:	State ID:
REFERENCE D	
	(mm/dd/yyyy)
	19B2. Job Code €€-€€€ (Fill in job code after interview is
	finished)
20. Did you att	end an adult daycare in the 12 weeks before [Reference Date/
	any place inside or outside your home where a household member spends at least 4 hours per week
under an adult	's care with at least two adults who do not live with you
	Yes1
	No
	Don't know/Not sure
	Refused9 (Skip to Q.21)
	20A. <i>If yes,</i> what type of care setting? [Read list if necessary]
	Home – care is provided in someone's home typically by one person1
	Center- care is provided typically in a commercial building with many providers and rooms_2
	Nanny / care provider share- two or more families have a single nanny / care provider to
	take care of their household member either full-time or part-time3
	Other4
	Specify:
	Don't know/Not sure7
	Refused9
SECTION 5: D	IET EXPOSURES
I'd like to ch	ange direction now and ask you about the foods you generally eat in a given week
	of water you drink.
and the mila	or rules you arrive
21. Did you red	ceive food / formula through a feeding tube called a G-tube or J-tube in the 12 weeks before
	te/
	Yes1
	No
	Don't know/Not sure
	Neiuseu3

22. In a typical week how frequently do you consume the following foods?

[READ LIST]	Often	Sometimes	Rarely	Never	DK/NS	Refused
	>5/week	2-5 /week	<2/ week	Never		
Eggs	1	2	4	5	7	9
Dairy (milk, yogurt)	1	2	4	5	7	9
Fresh raw Vegetables	1	2	4	5	7	9
Plant based protein (tofu, tempeh, seitan)	1	2	4	5	7	9
Red Meat (beef, lamb, pork, other game meat)	1	2	4	5	7	9
Poultry (chicken, turkey)	1	2	4	5	7	9
Seafood (fish, shellfish)	1	2	4	5	7	9

€ CASE Patient ID:_ REFERENC	€ CONTROL CE Date / / / (mm/dd/yyyy)	State ID:			
23. Which	Name of the water utilit	□ private well sy, if known	□ spring	unknown	
_	A. At home, what type of unk Tap water not treated in Tap water treated in the entry device) Commercially bottled w	n the home e home (for example, filte ater	often use for dr	inking (chose only	one)?
	6: MEDICAL HISTORY				
before [F	sets of questions are ab deference Date/_ ecific medications. Woul	/]. Medicine bot	ttles or record	ls may help yoເ	ı remember
DateYe	u take any antibiotics by mou //]? es on't know/Not sure	1 2 (Go to Q.28) 7 (Go to Q.28)	.2 weeks before	[Reference	

24A. Why did you take these antibiotic(s)?

Note: Subjects may indicate more than one reason (For example, if more than one course of antibiotics was taken for different illnesses or if one antibiotic was taken for and ear infection and a pneumonia)

[DO NOT READ LIST]	Yes	No
Acne	1	2
Bronchitis/ pneumonia	1	2
Dental cleaning	1	2
Ear, sinus, upper respiratory infection	1	2
Eye infection	1	2
Oral surgery	1	2

€ CASE € CONTROL	
Patient ID:	State ID:
REFERENCE Date//	
(mm/dd/yyyy)	

Skin or soft tissue infection (abscess	1	2
or cellulitis)		
Surgery	1	2
Urinary tract infection	1	2
-		
Urinary tract prophylaxis	1	2
Refused	9	9
DICALO	_	_
DK/NS	7	7
Other	1	2
	_	_
Specify:		

24B. Which antibiotic(s) did you take in the 12 weeks before [Reference Date____/____]? **[DO NOT READ LIST]**

[DO NOT READ LIST]			any weeks prior t	
		/		you take this antibiotic?
	YES	2-weeks	4-weeks	12-weeks
Amoxicillin	1			
Amoxicillin/Clavulanate	1			
Ampicillin	1			
Augmentin	1			
Azithromycin	1			
Bactrim	1			
Biaxin	1			
Ceclor	1			
Cefaclor	1			
Cefadroxil	1			
Cefdinir	1			
Ceftin	1			
Cefixime	1			
Cefuorixime	1			
Cefzil	1			
		If yes, How ma	any weeks prior t	o (Reference
		Date/	/) did	you take this antibiotic?
[DO NOT READ LIST]		2-weeks	4-weeks	12-weeks
Cephradine	1			
Ciprofloxacin or Cipro	1			
Clarithromyc	1			
Cleocin	1			
Clindamycin	1			
Dapsone	1			
Doxycycline	1			
Duricef	1			
Erythromycin	1			

€ CASE € CONTROL	
Patient ID:	State ID:
REFERENCE Date//	
(mm/dd/vvvv)	

Erythromycin/sulfa	1		
Flagyl	1		
Floxin	1		
Keflex	1		
Keftab	1		
Levofloxacin	1		
Levoquin	1		
Monurol	1		
Metronidazole	1		
Norfloxacin or Norflox	1		
Ofloxacin or Oflox	1		
Omnicef	1		
Penicillin or Pen VK	1		
Pediazole	1		
Septra	1		
Suprax	1		
Tetracycline	1		
Trimox	1		
Trimethoprim/Sulfa	1		
Vancomycin	1		
Zithromax or Z-Pak	1		
Clindamycin	1		
Other antibiotic 1	1		
Specify:	1		
	_		
Other antibiotic 2	1		
Specify:	1		
Don't know/Not sure	7		
Refused	9		

25. Did you use any antibiotic eye	drops in the 12 weeks before [Reference Date	/	_/]?
Yes	1			_
No				
Don't know/Not sure				
Refused				
25 A. <i>If yes,</i> what was the Polytrim (Polymyxin sulfat	e name of the drop (read list if necessary)?			
Ciloxan (Ciprofloxacin)	,			
Ocuflox (Ofloxacin)	3			
Vigamox, Moxeza (Moxifle				
Other	9			
Specify :				

€ CASE € CONTRO Patient ID: REFERENCE Date/_ (mm/dd.	1	State	e ID:				
regular use as use of the Maalox, Mylanta, Tagame Yes No Don't know/Not s Refused	ssive stom product at et, Zantac, ureure.see specify	nach acid, i least 3 da Prilosec, 1 2 (Ga 7 (Ga	heartburn, cays per weel or Nexium. o to Q.27) o to Q.27) o to Q.27)	or gastroeso k. Such me	phageal reflux o	disease (GERD)? We define	
[DO NOT READ	YES=	NO=2	If yes, Ho	ow many w	veeks prior	Marine in the	
LIST]	1		to (Reference Date//			If yes, in the 2 weeks before	
				1	nedication?		
			2 weeks	4 weeks	12 weeks		
Aciphex/rabeprazole	1	2					
Alka-Seltzer	1	2				1	
Maalox	1	2				I am now going to ask about medications that are	
Mylanta	1	2				given for many reasons	
Nexium/esomeprazole	1	2				including things like	
Pepcid/famotidine	1	2				chronic pain, depression, anxiety, to stop smoking,	
Prevacid/lansoprazole	1	2				and to help sleep. We are	
Prilosec/omeprazole	1	2				asking about these	
Protonix/pantoprazole	1	2				medications to determine	
Rolaids	1	2				if they could put people at risk for <i>C. diff</i> . Examples	
Tums	1	2				of these medications	
Tagamet/cimetidine	1	2				include: Prozac, Celexa,	
Zantac/ranitidine	1	2				Remeron, Paxil, and	
Other:	1	2				Trazadone.	
Don't Know/not sure	7	7					
Refuse	9	9				27. In the 12 weeks	
the product at lea Yes No Don't know/Not s Refused	st 3 days ure	per week. 1 2 (G 6 7 (G 6	o to Q.28) o to Q.28) o to Q.28)			before [Reference e define regular use as use of	

Patient ID: State ID: REFERDOCN OFFEREAD LISTI If yes, How many weeks prior (mm/dd/yyyy) to (Reference Date / /) did you take this medication? 2 weeks 4 weeks 12 weeks YES NO Amitriptyline 1 2 Anafranil (Clomipramine) 1 2 Asendin (Amoxapine) 1 2 Celexa, Cipramil (Citalopram) 1 2 Cymbalta (Duloxetine) 1 2 1 2 Effexor (Venlafaxine) Eldepryl, Emsam, Zelapar 1 2 (Selegiline) Escitalopram 1 2 Limbitrol 1 2 (Chlordiazepoxide/Amitriptyline) 1 2 Ludiomil, (Maprotiline) Luvox (Fluvoxamine) 1 2 2 Marplan, (Isocarboxazid) 1 Nardil, Nardelzine (Phenelzine 1 2 sulfate) 2 Norpramin (Desipramine) 1 Nortriptyline 1 2 Parnate, (Tranylcypromine) 1 2 2 Paxil (Paroxetine) 1 Pristiq (Desvenlafaxine) 1 2 1 2 Prozac, Sarafem, Fontex (Fluoxetine) Remeron, Avanza, Zispin 1 2 (Mirtazapine) 2 Savella, (Milnacipran) 1 Serzone, (Nefazodone) 1 2 2 Silenor, Prudoxin, Zonalon 1 (Doxepin) Surmontil (Trimipramine) 2 1 1 2 **Symbyax** (Olanzapine/fluoxetine) Tofranil, (Imipramine) 2 1 2 1 Trazadone Triptafen 1 2 (amitriptyline/perphenazine) 1 Viibryd (Vilazodone) 2 2 Vivactil, (Protriptyline) 1 2 1 Wellbutrin, Zyban (Bupropion) 1 2 Zoloft, Lustral (Sertraline) 1 2 Other: 58 Specify:___ Don't know/Not Sure 9 9 Refuse

If yes, in the

€ CASE	€ CONTROL		
Patient ID:		State ID:	
REFERENCE	Date //		
	(mm/dd/vvvv)	-	

2 weeks before

Now I am going to ask you about medical conditions you may have had.

DEAD LIGH	_			
READ LIST	Yes	No	DK/NS	Refused
Diabetes				
Heart attack				
Congestive heart failure				
Stroke				
High blood pressure				
Peripheral vascular disease				
(intermittent claudication, gangrene, peripheral arterial bypass)				
Chronic renal (kidney) failure				
→ If yes, are you on dialysis or awaiting				
dialysis?				
Chronic lung disease (COPD, emphysema)				
Asthma				
Cystic fibrosis				
Chronic Hepatitis B infection				
Chronic Hepatitis C infection				
Organ transplant				
Bone marrow transplant				
Leukemia or lymphoma				
Sickle cell disease (not sickle cell trait)				
Solid tumor cancer (e.g. bone, liver, brain)				
Short gut disease (bowel/ intestinal insufficiency				
Inflammatory bowel disease (Crohn's disease,				
Ulcerative colitis)				
Lupus				
Rheumatoid arthritis				
Depression				
Other illness:				

€ CASE € CONTROL Patient ID: REFERENCE Date//	State ID:	
(mm/dd/yyyy)		
SECTION 8: DEMOGRAPHICS		
Now I would like to ask you a t	few final questions.	
30. Do you consider yourself to be? () 1 Hispanic or Latino () 2 Not Hispanic or Latino () 7 Don't Know/Not Sure (DO NO () 9 Refused (DO NOT READ) () 10. Other racial category (DO N	OT READ)	
	d allow respondent to select one of ative sific Islander	ne following do you consider yourself or more]
32. What is your occupation?		_
33. What was your main type of hea	alth care coverage during (12 weeks og to read all the choices.	before Reference
Public insurance, such as Medicaid, A combination of private and public No health insurance DO NOT READ: Other [spec Don't know	r, PPO or a managed care plan, Medicare or state assistance programsurance cify] or not sure	am23487
Because education and incom of questions on these subjects		are, I'd like to ask you about a couple
1 Never attende 2 Elementary o	or year of school you completed? ed school or kindergarten only r middle school; 1 st -8 th grade chool; 9 th -11 th grade	

€ CASE €	CONTROL
Patient ID:	State ID:
REFERENCE Da	tte/ (mm/dd/yyyy)
	4 High school graduate; 12 th grade or GED
	5 College or technical school for 1-3 years
	6 College for 4 years, with or without a degree
	9 Refused
	home, what is the annual gross household income from all sources, including social security and as? Read Each Response in Order Until Respondent Agrees .
	0 Dependent college student
	1 Less than \$15,0005 Less than \$70,000
	2 Less than \$25,0006 \$70,000 or more
	3 Less than \$35,0007 Don't know or not sure
	4 Less than \$50,0009 Refused
36. Comments:	ast interview question. Thank you very much for your time and participation!
	-
37. Interview Co	ompleted? € Yes € No
38. Date of inte	rview://
39. Interviewer	initials:

€ CASE € CONTROL	
Patient ID:	_ State ID:
REFERENCE Date//	
(mm/dd/yyyy)	

Health Interview Appendix—Job Codes

OFFICE OF MANAGEMENT AND BUDGET - 1998 Standard Occupational Classification

29-0000 Healthcare Practitioners and Technical Occupations

29-1000 Health Diagnosing and Treating Practitioners

29-1010 Chiropractors

29-1020 Dentists

29-1021 Dentists, General

29-1022 Oral and Maxillofacial Surgeons

29-1023 Orthodontists

29-1024 Prosthodontists

29-1029 Dentists, All Other Specialists

29-1030 Dietitians and Nutritionists

29-1040 Optometrists

29-1050 Pharmacists

29-1060 Physicians and Surgeons

29-1061 Anesthesiologists

29-1062 Family and General Practitioners

29-1063 Internists, General

29-1064 Obstetricians and Gynecologists

29-1065 Pediatricians, General

29-1066 Psychiatrists

29-1067 Surgeons

29-1069 Physicians and Surgeons, All Other

29-1070 Physician Assistants

29-1080 Podiatrists

29-1110 Registered Nurses

29-1120 Therapists

29-1121 Audiologists

29-1122 Occupational Therapists

29-1123 Physical Therapists

29-1124 Radiation Therapists

29-1125 Recreational Therapists

29-1126 Respiratory Therapists

29-1127 Speech-Language Pathologists

29-1129 Therapists, All Other

29-1130 Veterinarians

29-1190 Miscellaneous Health Diagnosing and Treating Practitioners

29-1199 Health Diagnosing and Treating Practitioners, All Other

29-2000 Health Technologists and Technicians

29-2010 Clinical Laboratory Technologists and Technicians

29-2011 Medical and Clinical Laboratory Technologists

29-2012 Medical and Clinical Laboratory Technicians

29-2020 Dental Hygienists

29-2030 Diagnostic Related Technologists and Technicians

29-2031 Cardiovascular Technologists and Technicians

29-2032 Diagnostic Medical Sonographers

29-2033 Nuclear Medicine Technologists

29-2034 Radiologic Technologists and Technicians

29-2040 Emergency Medical Technicians and Paramedics

29-2050 Health Diagnosing and Treating Practitioner Support Technicians

29-2051 Dietetic Technicians

29-2052 Pharmacy Technicians

31-9094 Medical Transcriptionists

31-9095 Pharmacy Aides

31-9096 Veterinary Assistants and Laboratory Animal Caretakers

31-9099 Healthcare Support Workers, All Other

€ CASE € CONTROL Patient ID: REFERENCE Date / / (mm/dd/yyyy) State ID:
APPENDIX C2: COMMUNITY ASSOCIATED CLOSTRIDIUM DIFFICILE PEDIATRIC
CASE AND CONTROL INTERVIEW
SECTION 1: IDENTIFIERS***CASES AND CONTROLS******
1. € CASE € CONTROL
2. Study ID:
3. Reference date://
2 week before/
4 weeks before /
12 weeks before/
4. Age:YearsMonths
5. Sex € Male € Female
SECTION 2: ILLNESS QUESTIONS- ********CASES ONLY ****CONTROLS SKIP TO SECTION 3, Q. 10**********
Now I will ask you questions about your child's illness.
6. How many days did your child's diarrhea last?
Refused9
6A.On the worst day of your child's diarrhea, what was the approximate number of stools your child had in a 24-hour period? ≥3-<5 stools

Refused.....9

€ CASE	€ CONTROL								
Patient ID:			_ Sta	te ID:_					
REFERENCI	E Date/								
	(mm/dd/yy	yy)							
7 Did vour	shild have any	of the fellow	ina o	mnton	20.000	النابي المحامدة	a [bio/ bor] C	lifficila illaco	2
	child have any c EAD LIST]	Yes	ving sy No	mpton DK/N		iciated witi fused	n [nis/ ner] C. a	illiche illness	<i>5</i> ?
-	-				IS RE				
	ody stools	1	2 2	7		9			
Fev	-	1	2	7		9			
	usea :+:	1	2 2 2	7		9			
	niting	1	2	7		9			
	dominal pain		_	7		9			
Oth		1	2						
	Specify:								
8 Was you	r child hospitaliz	ed overnia	ht for l	hie/ he	erl C di	fficile illne	se?		
-	S	_	_	.1113/ 110	.ij C. ui	mone iiiie.			
					8A. I	f ves. whe	ere:	(name of
_	n't know/Not sur				1		ot be transmi		•
	used				<u>1103p</u>	<u>itui wiii ii</u>	ot be transmit	ieu io CDC	₹
1101	4004								
9. At the tin	ne of your child's	s C. difficile	diagr	nosis, v	was you	ır child tolo	d by a doctor o	r healthcare	provider that [she/
	other stomach						,		
	S				•				
				Go to (O.10)				
	n't know/Not sur		•		• ,				
	used								
	acca		(•		ę. <u> </u>				
9A.	If yes, what wa	s the name	e of the	e infec	tion?				
	•								
	[Read list i	f necessa	ry]	Yes	No	DK/NS	Refused		
	Campyloba	cter		1	2	7	9		
	E. coli			1	2	7	9		
	Listeria			1	2	7	9		
	Salmonella			1	2	7	9		
	Shigella			1	2	7	9		
	Vibrio			1	2	7	9		
	Yersinia			1	2	7	9		
	Cryptospor	idium		1	2	7	9		
	Giardia [']			1	2	7	9		
	Rotavirus			1	2		9		
	Norovirus			1	2	7	9		
	Other			<u>-</u>	2	·	•		
	G 11.0.			_	_				
	Specify:								
SECTION 3	: HEALTHCARE	CONTACTS	- CAS	SES AN	ID CON	TROLS			
			-					_	weeks <u>before</u>
Reference	e Date/_	/	_] to	[Refe	rence	Date	_//	_].	
						al office, h	ospital, or any	other medica	al facility in the 12
weeks before	re [REFERENCI	E DATE	1	/]?				

€ CASE € CONTROL		
Patient ID:	State ID:	
REFERENCE Date / /		
(mm/dd/yyyy)		
No	2 (Go to O.11)	
Don't know/Not sure		
Refused	• • •	

10A. I will now ask you about the types of places your child visited for [his / her] healthcare in that time period and when [he / she] made the visit. Did your child visit any of the following places?

[READ LIST]	YES=1	NO=2	O=2 DN/ NS=7	Refuse=9	How many weeks prior to (Reference			
					Date	//) did	
					your chil	d visit this	place?	
					2 weeks	4 weeks	12 weeks	
Ambulatory /								
Outpatient								
procedure center								
Ambulatory /								
Outpatient								
Surgery center								
Dental office								
Doctor's office								
ED								
Hemodialysis								
Hospital								
Outpatient lab								
Physical								
Therapy Center								
Urgent care								
Other								

IF NO TO ALL OPTIONS IN Q.10A then SKIP to Q.11

€ CASE € CONTROL Patient ID: REFERENCE Date/	State ID:	
(mm/dd/yyyy) 10B. during those visits in the 12 weeks the following procedures performed?	before (Reference Date//) did your child have any of

*****If Subject answered YES to dental visits only in 10A then only ask about last two items (oral surgery and dental cleaning)*********

[READ LIST]	YES=1	NO=2	DN/NS=7	7 Refuse=9	How many weeks prior to (Reference Date// did this procedure happen?			
					2 weeks	4 weeks	12 weeks	
Upper Endoscopy								
(Did the doctors								
pass a tube								
through								
your mouth or								
nose into your								
stomach?)								
Colonoscopy or								
Sigmoidoscopy								
(Did the doctors								
pass a tube into								
your								
rectum to look into								
your								
colon/bowel?)								
X-ray that required								
GI Prep								
(Did you have an								
X-ray performed								
where								
you had to								
swallow								
something first?)								
Chemotherapy								
Surgery in an								
operating room								
→If yes, Specify								
type:								
Other Medical								
Procedure:								
Oral Surgery								

Patient ID:							
aliciil iD		State	: ID:				
REFERENCE Date	//						
(mm/	(dd/yyyy)						
Dental Cleaning							
L1. Did your child visit a	a person in o	or accompa	anv anvone to a	a doctor's office.	dental office	. hospital, nu	rcina homa
						,	ising nome,
or any other medical fa	cility in the 1						ising nome,
or any other medical fa Yes		12 weeks b					rsing nome,
Yes		12 weeks b 1	efore [Reference				ising nome,
Yes No		12 weeks b 1 2 (G	efore [Referend o to Q.12)				ising nome,
Yes No Don't know/No	t sure	12 weeks be 1 2 (G c 7 (G c	efore [Referend to Q.12) to Q.12)				ising nome,
Yes No	t sure	12 weeks be 1 2 (G c 7 (G c	efore [Referend to Q.12) to Q.12)				ising nome,
Yes No Don't know/No	t sure	12 weeks be 1 2 (G c 7 (G c	efore [Referend to Q.12) to Q.12)				ising nome,
Yes No Don't know/No Refused	t sure	12 weeks b 1 2 (Go 7 (Go 9 (Go	efore [Reference to Q.12) to Q.12) to Q.12)		/]?	

€ CASE	€ CONTROL		
Patient ID:		State ID:_	
REFERENCE	Date//		
	(mm/dd/vvvv)		

		1	ı	1	1		
[READ LIST]	YES=1	NO=2	DN/NS=7	Refuse=9	How many weeks prior to (Reference		
					Date) did
						d visit this	
					2 weeks	4 weeks	12
					- *************************************	. ,, eens	weeks
Ambulatory /							
Outpatient							
procedure center							
Ambulatory /							
Outpatient							
surgery center							
Dental office							
Doctor's office							
ED							
Hemodialysis							
Hospital							
Long term care/							
skilled nursing							
facility							
Outpatient lab							
Physical							
Therapy Center							
Urgent care							
Other							
HOUSELIOLD CONT	ACTC	1	1	1	ı	1	1

HOL	ISFHOL	D CON	TACTS

The next few questions are about your chi	ild and persons	who lived with your	child during the 12
weeks before [Reference Date/_	<i>_</i>].		

12. Excluding your child, how many people lived in your child's household during that time?

12A. How many household members, not including your child, were in each of these age groups? [List

number of people in each group] Ages €<1 €1 to 3 €4 to 10 €11 to 18 €19 to 34 €35 to 59 € 60+

13. Did any household member excluding your child wear diapers? (Including adults in diapers)

Yes.....1 No.....2 Don't know/Not sure.....7 Refused.....9

14. Did any household members excluding your child attend a group childcare setting, daycare, or adult daycare? We consider daycare to be any place inside or outside your home where a household member spends at least 4 hours per week under an adult's care with at least two other people who do not live with your child.

€ CASE € CONTROL		
Patient ID:	State ID:	
REFERENCE Date//		
(mm/dd/yyyy)		
Yes	1	
	2 (Go to Q.15)	
	7 (Go to Q.15)	
Relusea		

14A. *If yes*, which household members attended daycare and what type of daycare setting was it? *[Read description of setting types if necessary]*

AGE Group	Type of Daycare Setting					
	Home	Center	Nanny	Other (specify)	Don't know	Refused
< 1	1	2	3		7	9
1 to 3	1	2	3		7	9
4 to 10	1	2	3		7	9
11 to 17	1	2	3		7	9
18 to 34	1	2	3		7	9
35 to 59	1	2	3		7	9
60 +	1	2	3		7	9

Home – care is provided in someone's home typically by one person
 Center- care is provided typically in a commercial building with many providers and rooms.
 Nanny / care provider share- two or more families have a single nanny / care provider to take care of their household member either full-time or part-time

L5. In the 12 weeks before [Reference Date nospital?	_/	<u> </u>	_)], did any household member stay overnight in a
Yes1			
No2			
Don't know/Not sure7			
Refused9			
Reluseu9			
L6. In the 12 weeks before [Reference Date nursing home?	_/	<u>/</u>	_)], did any household member stay overnight in a
Yes1			
No2			
Don't know/Not sure7			
Refused9			
diarrhea?	_/		_)], did anyone else in your child's household have
Yes1			
No2 (Go t	o Q.19))	
Don't know/Not sure7 (Go t			

CASE ent ID:	€ CONTROL State ID:						
ERENCE	E Date/						
	(mm/dd/yyyy)						
Refu	used9 (Go to Ç	Q. 19)					
18A	. If yes, did your child assist this person	n with to	ileting	(including	diaper chang	es)?	
	Yes1 No2						
	Don't know/Not sure7						
	Refused9						
18B	. Was this person diagnosed with <i>C. di</i>	fficile?					
	Yes1 No2						
	Don't know/Not sure7						
	Refused9						
Did anv	of your child's household members wo	rk at or v	olunte	er in anv	canacity at a	hospital other me	-dical
	any facility where patient care is provide						,uicai
	/)]?					•	
	1						
	2 (Go to (
	't know/Not sure7 (Go to C						
Reit	used9 (Go to (<i>2.20)</i>					
19Δ	. <i>If yes,</i> what type of healthcare setting	12					
15/	(READ LIST)	Yes	No	DK/NS	Refused		
	Hospital	1	2	7	9		
	Emergency department	1		7	9		
	Doctor's office	1	2	7	9		
	Dentist	1	2	7	9		
	Long term care (skilled nursing fac		2		9		
	Hemodialysis facility	1	2	7	9		
	Other facility	1	2				
	Chooif						
	Specify:						
	_						
19B	. Did their job involve direct physical co	ontact wit	h patie	ents? For	example toucl	hing the patient to	help h
get	out of a chair		•		·		·
	Yes1						
	No2						
	Don't know/Not sure7						
	Refused9	(Go to Ç).20)				

19C. *If yes,* what was their main job?

€ CASE Patient ID: REFERENCE [€ CONTROL Date/	State ID:
20. Did your c Date /	child attend a group child	EE-EEE (Fill in job code after interview is finished) dcare or daycare in the 12 weeks before [Reference der daycare to be any place inside or outside your home where your child
	St 4 hours per week und Yes No Don't know/Not sure.	ler an adult's care with at least two children who do not live with you
20A. <i>i</i>	Home – care Center- care is provid Nanny / care take Other	dcare setting? [Read list if necessary] is provided in someone's home typically by one person1 ded typically in a commercial building with many providers and rooms2 provider share- two or more families have a single nanny / care provider to care of their household member either full-time or part-time34 cify: Not sure7
Section 5: F	Don't know/N Refused DIET EXPOSURES	
l'd like to ch	<u> </u>	and ask you about the foods your child generally eats in a given r child drinks.
	child receive food / formu ate/)]	ula through a feeding tube called a G-tube or J-tube in the 12 weeks before ?
	Yes No Don't know/Not sure.	2

22. In a typical week how frequently does your child consume the following foods?

Refused.....9

[READ LIST]	Often	Sometimes	Rarely	Never	DK/NS	Refused
	>5/week	2-5 /week	<2/ week	Never		
Eggs	1	2	4	5	7	9
Dairy (milk, yogurt)	1	2	4	5	7	9
Fresh-cut raw Vegetables	1	2	4	5	7	9
Plant based protein (tofu, tempeh, seitan)	1	2	4	5	7	9
Red Meat (beef, lamb, other game meat)	1	2	4	5	7	9

€ CAS	SE € CONTROL							
Patient		State	ID:					
REFER	ENCE Date/_ 	<u>/</u>						
	, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,							
	Poultry (chicken, tu	rkey)	1	2	4	5	7	9
	Seafood (fish, shellfis	h)	1	2	4	5	7	9
23. Wh		lity □ prive prive prive prive □ priv	vate well own	□ spr	ing □	unknown	□ othe 	r
	23A. At home, what Tap water to entry deviceCommercia	not treated in the ho reated in the home	rater does y ome (for examp	our child mos	st often use f	or drinking	(chose onl	
24 Du	ring the first 6-month			sav: (read cl	hoices)			
24. Du	Almost 100% of fee	-	-	• `	•	1		
		•		,				
	Most feedings (abo	,						
	About half (or 50%)	_						
	Most feedings (abo	ut 75%) were formu	ıla and the	rest were bre	ast milk	4		
	Almost 100% of fee	dings were formula	with no or	very little bre	ast milk	5		
	Don't know/Not sur Refused							
SECTION	ON 6: MEDICAL HIST	ORY						
before	ext set of question e [Reference Date specific medicati]. Medicin	e bottles o	r records n	nay help y	ou reme	12 weeks mber
	your child take any your c	1 2 (Go	to Q.27)	her] vein in t	he 12 weeks	before [Re	eference	

26. Why did your child take these antibiotics?

Note: Subjects may indicate more than one reason (For example, if more than one course of antibiotics was taken for different illnesses or if one antibiotic was taken for and ear infection and a pneumonia)

€ CASE	€ CONTROL		
Patient ID:		State ID:_	
REFERENCE	Date/		
	(mm/dd/yyyy)		

[DO NOT READ LIST]	Yes	No
Bronchitis/ pneumonia	1	2
Dental cleaning	1	2
Ear, sinus, upper respiratory infection	1	2
Eye infection		
Oral surgery		
Skin or soft tissue infection (abscess or cellulitis)	1	2
Surgery	1	2
Urinary tract infection	1	2
Urinary tract infection prophylaxis		
DK/NS	7	7
Refused	9	9
Other	1	
Specify:	<u> </u>	<u> </u>

26A. Which antibiotic(s) did your chil [DO NOT READ LIST]	d take in the 12 weeks before [Reference Date/]?
	If yes, How many weeks prior to (Reference

€ CASE	€ CONTROL	
Patient ID:		State ID:
REFERENCE	Date/	
	(mm/dd/yyyy)	

		Date / /)	did your child	take this antibiotic
[DO NOT READ LIST]		2-weeks	4-weeks	12-weeks
	Yes	Yes	Yes	Yes
Amoxicillin	1			
Amoxicillin/Clavulanate	1			
Ampicillin	1			
Augmentin	1			
Azithromycin	1			
Bactrim	1			
Biaxin	1			
Ceclor	1			
Cefaclor	1			
Cefadroxil	1			
Cefdinir	1			
Ceftin	1			
Cefixime	1			
Cefuorixime	1			
Cefzil	1			
Cephradine	1			
Ciprofloxacin or Cipro	1			
Clarithromyc	1			
Cleocin	1			
Clindamycin	1			
Dapsone	1			
Doxycycline	1			
Duricef	1			
Erythromycin	1			
Erythromycin/sulfa	1			
Flagyl	1			
Floxin	1			
Keflex	1			
Keftab	1			
Levofloxacin	1			
Levoquin	1			
Monurol	1			
Metronidazole	1			
Norfloxacin or Norflox	1			
Ofloxacin or Oflox	1			
Omnicef	1			
Penicillin or Pen VK	1			
Pediazole	1			
Septra	1			
Suprax	1			
Capian	-			
Q. 26A CONTINUED		If yes, How many weeks prior to (Reference Date /) did your child take this antibiotic		
[DO NOT READ LIST]		2-weeks	4-weeks	12-weeks
[DO NOT NEAD EIGH]		~ VVCCN3	-T-VVCCR3	TE-MCCK3

€ CASE	€ CONTROL					
Patient ID:		State ID:				
REFEREN	CE Date//					
	(mm/dd/yyyy)					
	Trimox	1				
	Trimethoprim/Sulfa	1				
	Vancomycin	1				
	Zithromax or Z-Pak	1				
	Clindamycin	1				
	Other antibiotic 1	1				
	Specify:	1				
		_				
	Other antibiotic 2	1				
	Specify:	1				
	Don't know/Not sure	7				
	Refused	9				
27. Did vo	our child use any antibiotic eye	drops in the	12 weeks before [F	Reference Date	1 1	1?
-	es	•				
N	lo	2 (Go to Q.2	28)			
	on't know/Not sure					
R	efused	9 (Go to Q.2	P8)			
			•			
2	7 A. <i>If yes,</i> what was the name	of the drop (read list if necess	sary)?		
	olytrim (Polymyxin sulfate / TM					
	iloxan (Ciprofloxacin)					
C	cuflox (Ofloxacin)	3				
	igamox, Moxeza (Moxifloxacin)					
	ther					
9	Specify :	_				

€ CASE € CONTROL	
Patient ID:	State ID:
REFERENCE Date// 	
medications to treat excessive stomac	Date/
Yes	1
No	2 (Go to Q.29)
Don't know/Not sure	7 (Go to Q.29)
Refused	9 (Go to Q.29)

28A. *If Yes*, please specify which medicine your child regularly took in those 12 weeks.

[DO NOT READ LIST]	YES=	NO=2	How many weeks prior to (Reference Date//) did your child take this medication?		
			2 weeks	4 weeks	12 weeks
Aciphex/rabeprazole	1	2			
Alka-Seltzer	1	2			
Maalox	1	2			
Mylanta	1	2			
Nexium/esomeprazole	1	2			
Pepcid/famotidine	1	2			
Prevacid/lansoprazole	1	2			
Prilosec/omeprazole	1	2			
Protonix/pantoprazole	1	2			
Rolaids	1	2			
Tums	1	2			
Tagamet/cimetidine	1	2			
Zantac/ranitidine	1	2			
Other:	1	2			
Don't Know/not sure	7	7			
Refuse	9	9			

If yes, in the 2 weeks before

€ CASE € CONTROL Patient ID:	State ID:
REFERENCE Date// (mm/dd/yyyy)	
pain, depression, anxiety, and to help	ons that are given for many reasons including things like chronic sleep. We are asking about these medications to determine if they camples of these medications include: Prozac, Celexa, Remeron, Paxil,
29. In the 12 weeks before [Reference D medications? We define regular use as	pate/

nt ID:SI	tate ID:_		How many weeks prior to (Reference Date//) did you		
				e this medi	
	YES	NO	2 weeks	4 weeks	12 weeks
Amitriptyline	1	2			
Anafranil (Clomipramine)	1	2			
Asendin (Amoxapine)	1	2			
Celexa, Cipramil (Citalopram)	1	2			
Cymbalta (Duloxetine)	1	2			
Effexor (Venlafaxine)	1	2			
Eldepryl, Emsam, Zelapar	1	2			
(Selegiline)	1	~			
Escitalopram	1	2			
Limbitrol	1	2			
	1	_			
(Chlordiazepoxide/Amitriptyline)	1	2			
Ludiomil,(Maprotiline)	1	2			
Luvox (Fluvoxamine) Marplan (Icocarbovazid)	1	2			
Marplan, (Isocarboxazid)					
Nardil, Nardelzine (Phenelzine sulfate)	1	2			
Norpramin (Desipramine)	1	2			
Nortriptyline	1	2			
Parnate,(Tranylcypromine)	1	2			
Paxil (Paroxetine)	1	2			
Pristiq (Desvenlafaxine)	1	2			
Prozac, Sarafem, Fontex (Fluoxetine)	1	2			
Remeron, Avanza, Zispin (Mirtazapine)	1	2			
Savella, (Milnacipran)	1	2			
Serzone, (Nefazodone)	1	2			
Silenor, Prudoxin, Zonalon (Doxepin)	1	2			
Surmontil (Trimipramine)	1	2			
Symbyax	1	2			
(Olanzapine/fluoxetine)					
Tofranil, (Imipramine)	1	2			
Trazadone	1	2			
Triptafen	1	2			
(amitriptyline/perphenazine)					
Viibryd (Vilazodone)	1	2			
Vivactil, (Protriptyline)	1	2			
Wellbutrin, Zyban (Bupropion)	1	2			
Zoloft, Lustral (Sertraline)	1	2			
Other:		8	30		
Don't know/Not Sure	7	7			
Refuse	9	9			

If yes, in the

€ CASE € CONTROL	
Patient ID:	State ID:
REFERENCE Date//	
(mm/dd/yyyy)	

2 weeks before

Now I am going to ask you about medical conditions your child may have had.

30. **Prior to** [Reference Date___/____], were you ever told by a medical provider that your child had any of the following medical conditions? **[READ LIST – including information in parentheses]**

€ CASE	€ CONTROL		
Patient ID:		State ID:	
REFERENCE	Date//	_	
	(mm/dd/yyyy)		

READ LIST	Yes	No	DK/NS	Refused
Congenital heart disease				
Specify:				
Diabetes				
Chronic renal (kidney) failure				
If yes, is your child on dialysis or awaiting				
dialysis?				
Chronic lung disease (BPD)				
Asthma				
Cystic fibrosis				
Organ transplant				
Bone marrow transplant				
Leukemia or lymphoma				
Sickle cell disease (not sickle cell trait)				
Cancer (e.g. bone, liver, brain)				
Short gut disease (bowel/ intestinal insufficiency)				
Depression				
Born by C-section?				
Stay in the NICU at birth?				
If yes, was your child premature?				
How many weeks premature?				
If yes, how many weeks in the NICU?				
Other illnesses:				

31. There is some evidence that how much you weigh may effect infection with C. difficile. What are your child's most recent height or length and weight?

	-		Sometimes children's doctors give parents records or charts ave these I can wait while you get them]
Refused	9		
Height/ length:	Ft	<u>in</u> (or	cm)
Weight:	_lbs (or _	Kg)	

€ CASE € CONTROL	
Patient ID:	State ID:
REFERENCE Date///	
(
Crorion O. Drivoor and	
SECTION 8: DEMOGRAPHICS	
Now I would like to ask yo	a few final questions.
-	·
32. Do you consider your child	be? [Read responses 1 & 2]
() 1 Hispanic or Latino	
() 2 Not Hispanic or Latino	
() 7 Don't Know/Not Sure (Do	
() 9 Refused (DO NOT REAL	
() 10. Other racial category (D	O NOT READ)
22 Lam going to road a list of re	cial categories. Which one or more of the following do you consider your child to
	d allow respondent to select one or more]
() 1 White/Caucasian	a allow respondent to select one of more]
() 2 Black or African-America	
() 3 American Indian or Alask	
() 4 Native Hawaiian or Other	
() 5 Asian	
() 7 Don't Know/Not Sure (DC	NOT READ)
() 9 Refused (DO NOT READ	
() 10. Other racial category (E	
	type of health care coverage during (12 weeks before Reference
Date/ and	Reference Date/
Drivete incurence such as and	MO DDO or a managed care plan
	MO, PPO or a managed care plan1 aid. Medicare or state assistance program 2
	aid, Medicare or state assistance program2 blic insurance3
DO NOT READ: Other	specify]8
Don't k	now or not sure 7
Refuse	

I have just a few more questions about the parent or guardian who cares for [child's name] most often.

Because education and income can affect access to healthcare, I'd like to ask you about a couple of questions on these subjects.

€ CA	
Patien	t ID: State ID: RENCE Date / /
	(mm/dd/yyyy)
35. W	/hat is the highest grade or year of school that any of the household members completed? Please answer this question based on the highest level of education in your household
	1 Never attended school or kindergarten only
	2 Elementary or middle school; 1 st -8 th grade
	3 Some high school; 9 th -11 th grade
	4 High school graduate; 12 th grade or GED
	5 College or technical school for 1-3 years
	6 College for 4 years, with or without a degree
	9 Refused
Beca	use income can affect access to healthcare, I'd like to ask you about annual income.
36.	In your child's home, what is the household income from all sources? READ EACH RESPONSE IN ORDER UNTIL
30.	RESPONDENT AGREES.
	1 Less than \$15,0005 Less than \$70,000
	2 Less than \$25,0006 \$70,000 or more
	3 Less than \$35,000 7 Don't know or not sure
	4 Less than \$50,0009 Refused
That	was my last interview question. Thank you very much for your time and participation!
27 C	omments:
37. C	omments.
38. In	terview Completed? € Yes € No
39 D:	ate of interview: / /
50. D	ate of interview://(mm/dd/yyyy)
40. In	terviewer initials:

Health Interview Appendix—Job Codes

OFFICE OF MANAGEMENT AND BUDGET - 1998 Standard Occupational Classification

29-0000 Healthcare Practitioners and Technical Occupations

29-1000 Health Diagnosing and Treating Practitioners

29-1010 Chiropractors

29-1020 Dentists

29-1021 Dentists, General

29-1022 Oral and Maxillofacial Surgeons

29-1023 Orthodontists

29-1024 Prosthodontists

29-1029 Dentists, All Other Specialists

29-1030 Dietitians and Nutritionists

29-1040 Optometrists

29-1050 Pharmacists

29-1060 Physicians and Surgeons

29-1061 Anesthesiologists

29-1062 Family and General Practitioners

29-1063 Internists, General

29-1064 Obstetricians and Gynecologists

29-1065 Pediatricians, General

29-1066 Psychiatrists

29-1067 Surgeons

29-1069 Physicians and Surgeons, All Other

29-1070 Physician Assistants

29-1080 Podiatrists

29-1110 Registered Nurses

29-1120 Therapists

29-1121 Audiologists

29-1122 Occupational Therapists

29-1123 Physical Therapists

29-1124 Radiation Therapists

29-1125 Recreational Therapists

29-1126 Respiratory Therapists

29-1127 Speech-Language Pathologists

29-1129 Therapists, All Other

29-1130 Veterinarians

29-1190 Miscellaneous Health Diagnosing and Treating Practitioners

29-1199 Health Diagnosing and Treating Practitioners, All Other

29-2000 Health Technologists and Technicians

29-2010 Clinical Laboratory Technologists and Technicians

29-2011 Medical and Clinical Laboratory Technologists

29-2012 Medical and Clinical Laboratory Technicians

29-2020 Dental Hygienists

29-2030 Diagnostic Related Technologists and Technicians

29-2031 Cardiovascular Technologists and Technicians

29-2032 Diagnostic Medical Sonographers

29-2033 Nuclear Medicine Technologists

29-2034 Radiologic Technologists and Technicians

29-2040 Emergency Medical Technicians and Paramedics

29-2050 Health Diagnosing and Treating Practitioner Support Technicians

29-2051 Dietetic Technicians

29-2052 Pharmacy Technicians

29-2053 Psychiatric Technicians

29-2054 Respiratory Therapy Technicians

29-2055 Surgical Technologists

€ CASE € CONTROL	
Patient ID:	State ID:
REFERENCE Date// 	
29-2056 Veterinary Techno	ologists and Technicians

29-2060 Licensed Practical and Licensed Vocational Nurses

29-2070 Medical Records and Health Information Technicians

29-2080 Opticians, Dispensing

29-2090 Miscellaneous Health Technologists and Technicians

29-2091 Orthotists and Prosthetists

29-2099 Health Technologists and Technicians, All Other

29-9000 Other Healthcare Practitioners and Technical Occupations

29-9010 Occupational Health and Safety Specialists and Technicians

29-9011 Occupational Health and Safety Specialists

29-9012 Occupational Health and Safety Technicians

29-9090 Miscellaneous Health Practitioners and Technical Workers

29-9091 Athletic Trainers

29-9099 Healthcare Practitioners and Technical Workers, All Other

31-0000 Healthcare Support Occupations

31-1000 Nursing, Psychiatric, and Home Health Aides

31-1010 Nursing, Psychiatric, and Home Health Aides

31-1011 Home Health Aides

31-1012 Nursing Aides, Orderlies, and Attendants

31-1013 Psychiatric Aides

31-2000 Occupational and Physical Therapist Assistants and Aides

31-2010 Occupational Therapist Assistants and Aides

31-2011 Occupational Therapist Assistants

31-2012 Occupational Therapist Aides

31-2020 Physical Therapist Assistants and Aides

31-2021 Physical Therapist Assistants

31-2022 Physical Therapist Aides

31-9000 Other Healthcare Support Occupations

31-9010 Massage Therapists

31-9090 Miscellaneous Healthcare Support Occupations

31-9091 Dental Assistants

31-9092 Medical Assistants

31-9093 Medical Equipment Preparers

31-9094 Medical Transcriptionists

31-9095 Pharmacy Aides

31-9096 Veterinary Assistants and Laboratory Animal Caretakers

31-9099 Healthcare Support Workers, All Other

APPENDIX D: Introduction letter For Participants

INTRODUCTION LETTER FOR PARTICIPANTS

Note: Letter will be on health department or Emerging Infections Program letterhead only for sites that require introduction letter

MONTH, DAY, YEAR

JANE DOE 100 MAIN STREET ANYTOWN, USA 11111

Dear Ms. Doe:

The [HEALTH DEPT/EIP NAME] and the Centers for Disease Control and Prevention are working together to assess factors that may put persons under risk of developing Clostridium difficile or C. diff infection outside of the hospital. C. diff is a germ that can cause severe diarrhea and it can be very hard to treat. People in hospitals are at most risk of getting this germ, but C. diff can also occur in people who have not been hospitalized. We don't know why people in the community who have not been hospitalized get this infection, but to help us understand possible reasons we need to interview people who were sick with C. diff as well as people who were not sick with C. diff. The goal of this study is to learn more about C. diff in people living in the community so that steps can be taken to prevent this infection. We are contacting you because either you or someone in you household has developed C. diff infection or you or someone in your home lives in the same area and is around the same age as someone who developed this infection.

Someone from [HEALTH DEPT/EIP NAME] may call you and ask if you would like to participate. If you agree, the person from the health department will ask you a series of questions about your health and healthcare exposures (or about your child's health and healthcare exposures). The interview will take about 30 minutes. After your participation, a \$20 gift card will be sent to you to show our appreciation for your time and effort.

Being in this study is voluntary. Most likely there will be no direct value to you for taking part in this study. However, the results of this study will help doctors plan ways to prevent infections with this germ. There are no risks or costs to you for participating. If you choose not to be in the study, your health care will not be affected in any way. We hope you will participate. If you do not want to take part or hear more about this study, please send back the enclosed postcard. Thank you for your help.

Sincerely,

[STUDY COORDINATOR'S NAME]
[TITLE]

Enclosure: postcard

Appendix D: Post Card

REFUSAL POSTCARD

POSTCARD
Front: [STUDY COORDINATOR NAME] [ADDRESS]
Back: Participant number [HEALTH DEPT/EIP NAME] use only
Please do not contact me. I do not want to participate in the study.

Appendix E: Thank You Letter

THANK YOU LETTER TO EVALUATION PARTICIPANTS

Note: Letter will be on health department of Emerging Infections Program letterhead Reading level: Grade 7.8 using Flesch-Kincaid Scale

Month, day, year

Jane Doe 100 Main Street Anytown, USA 11111

Dear Ms. Doe:

Thank you very much for participating in this study to learn more about *Clostridium difficile* in people in the community. Your help will assist us in learning more about this disease.

To thank you for your time participating in this important evaluation, we are sending you a \$20 certificate as a token of our appreciation. Also enclosed is a copy of the consent form for your records.

Your participation is much appreciated.

Please call me at [phone number] if you have any questions.

Sincerely,

EIP Representative Contact information

Enclosure: Gift Certificate, Consent Form